presentation of pharmaceutical company

Emerging from disruption: The future of pharma operations strategy

In the past, many pharmaceutical companies (pharmacos) deprioritized operations strategy in the face of competing business pressures. This is now changing. Factors such as the COVID-19 pandemic, inflation, geopolitics, new therapeutic modalities, and new ways of working make it vital for pharmacos to carefully reconsider their long-term choices in sourcing, manufacturing, and supply chain.

Now is exactly the right time for this renewed emphasis on operations strategy, as pharmacos emerge from two years of intense firefighting. Succeeding in pharma under these new and challenging conditions will require succeeding in operations.

The focus for operational leaders may need to shift from the prevailing emphasis on continuous improvement—including cost savings, quality assurance, and constant readiness to deliver—to longer-term external challenges. These include high inflation and an increase in complexity and risk, as well as the compounding effects these forces have on each other.

Pharma operations leaders now have an opportunity to deliver even greater value to their organizations by achieving this shift in focus, but they must act quickly to keep abreast of the challenges confronting the industry. The effort will require enormous mobilization and thoughtful prioritization. This task will fall to leadership; only the CEO and head of operations are in the right positions to make it happen.

This article explores the challenges facing pharma leaders and the steps they can take to develop a more strategic, long-term, and integrated approach to operations strategy. It presents questions leaders can ask as they design the solutions needed to make sure operations can protect enterprise continuity while still delivering to patients.

A perfect storm of external challenges

The pharma industry is facing a multitude of challenging trends (Exhibit 1). Global demand is growing rapidly, and the unprecedented need for COVID-19 vaccines and therapeutics has put additional pressure on the industry. The industry’s ability to find innovative solutions to deliver COVID-19 vaccines while still meeting overall demand is a remarkable achievement, but rising global demand is still a significant challenge for the industry in the long term.

The product landscape also is changing swiftly. New modalities, such as cell and gene therapy and mRNA vaccine technology, have increased from 11 to 21 percent of the drug development pipeline—the fastest growth ever seen in the sector. This change is likely to bring more fragmentation of technology, new supply chains, and unique product life cycles.

In addition to these industry-specific trends, pharma has also been affected by broader global trends, such as supply chain pressures. While the pharma industry is considered somewhat protected by its high inventory levels and long-standing dual sourcing, over a given ten-year period, the likelihood of supply chain disruptions still represents a potential loss of 25 percent of EBITA . Inflation has risen in recent months to levels not seen for decades, leading to increasing costs for labor, raw materials, and transportation. This is over and above the persistent price pressures pharma is already facing, particularly in generics. Since pharma customers are not expected to fully absorb these cost increases, profit margins are under pressure.

Meanwhile, increased state interventions and protectionist trade policies are creating new pressures on manufacturing networks and could drive increased regionalization. This would be a capital-intensive exercise: to regionalize just 10 percent of current vaccine trade in one particular geographical region, governments would need to invest an estimated $100 million.

Would you like to learn more about our Operations Practice ?

The pharma industry is also facing talent shortages linked to wider labor market trends, including the 20 percent increase in demand for STEM-related roles across the life sciences industry in the United States. The current pool of pharma digital talent is at least 14 percent lower than demand, and many companies are finding it challenging to recruit technical talent. Compounding this challenge is the rise of remote working, which has increased employee expectations for flexibility. In response, nearly all pharmacos are experimenting with hybrid working models.

A few major trends point to an industry tailwind; one of them is the advancement of digital and analytics tools. Digital tools, robots, and sensors are becoming cheaper and easier to access, and they can be used to capture all manner of raw data. In addition, edge computing and cloud analytics are providing real-time optimization and transparency. Pharmacos are working to leverage the power of data to become more agile and resilient. However, to date, no pharmaco has emerged as a true global leader in this field.

The pharma industry is facing a multitude of industry-specific and global trends. But a few major trends point to an industry tailwind; one of them is the advancement of digital and analytics tools.

Each of these global trends represents significant challenges in and of itself, and the trends may be compounded and strengthened through their interactions. This compounding effect can add to the complexity of evaluating an effective strategic response.

Major implications for pharma

These global trends have six major implications for pharmacos: rising operational complexity, increasing risk, shifting capability requirements, higher capital expenditure requirements, variable-cost increases, and opportunities for savings (Exhibit 2).

Operations leaders may need to become comfortable navigating a more complex ecosystem as they respond to increased operational complexity. Risks may increase due to rising environmental, social, and governance (ESG) expectations and skills gaps, while new modalities and digital acceleration will also likely lead to a shift in capability requirements. This could necessitate reskilling and upskilling of staff, as well as a renewed focus on recruiting from outside of the pharma industry.

From a cost perspective, the pharma industry may see significantly increased capital expenditure requirements related to the construction of new sites and new digital infrastructure. Increases are also likely in variable costs in areas such as raw materials, transportation, and employee attrition, reskilling, and salaries.

Future of pharma operations

Pharma companies are experiencing a wave of innovations – from new treatment modalities, to smart machines, advanced analytics, and digital connectivity.

Although these implications are challenging, they may represent possible opportunities for savings in several areas. For example, ESG commitments on waste reduction could reduce costs, as could successful digital implementation. However, the challenge lies in monetizing these cost savings, given that the industry has long created value largely through revenue expansion rather than through cost savings.

Rising to the challenge: Actions to deliver value

To respond to these challenges, pharmaco leaders may now need to emphasize the importance of their operations strategy. They should consider taking a longer-term view and scaling activity across four key themes: network strategy and resilience, digital, operating model, and talent.

Expand focus on longer-term, transformative solutions

Operations leaders can address these challenges through several short-term and long-term responses. For example, problems associated with a more unpredictable supply chain could be addressed with a short-term approach of increasing inventory or a long-term initiative to establish an end-to-end supply chain digital nerve center.

Short-term levers can be an important part of the total response but are insufficient to fully mitigate the challenges facing the industry. To respond effectively, companies may need to accelerate new ways of working and embrace long-term thinking. This will require concrete action with a focus on making sure that strategies are put in place to weather the long-term headwinds the industry is facing.

Accelerate and scale responses across four strategic domains

To identify the actions that pharmacos could take, it may help to group these in terms of four strategic domains: network and resilience, digital strategy, operating model and ecosystem, and talent strategy (Exhibit 3). While these themes are likely to be familiar to any business leader, they now require a substantial shift in mindset. Acting on them also calls for a large investment of resources.

• Plan for and manage future resilience and reliability needs . Recent supply chain disruptions have pushed supply chain resilience up corporate agendas. Companies have been forced into reactive modes that employ short-term levers like building inventory. However, companies could better position themselves by solving multiple variables and building resilience into their operations strategy through longer-term actions like network design and dual sourcing.
• Scale end-to-end adoption of digital and automation . Digital has proven itself highly valuable to pharma operations. However, many companies struggle to move from targeted, single use cases to a fully scaled suite of solutions. And while the adoption of full-scale digital solutions can require heavy investment—around $50 million to $100 million per year for two to three years—the rewards can include significant cost savings, improved quality, and increased resilience, as well as greater employee effectiveness. Companies that truly scale and implement digital can better protect themselves from the pressures of the forces increasing costs for the industry. More and more companies are moving toward network-wide and end-to-end digitization; to date, the World Economic Forum has recognized 103 as “lighthouses,” based on their advanced application of digital technologies . Johnson & Johnson, for example, has successfully launched multiple Industry 4.0 lighthouses, including some focused on end-to-end patient connectivity and order fulfillment.
• Expand adoption of end-to-end partner ecosystems . Companies could also consider changing their operating model from a traditional hub configuration around originators to an end-to-end ecosystem of true strategic partners. More than 50 percent of companies already expect to intensify their collaboration models with other industry players through, for example, service agreements, joint ventures, or eco­systems. Some are already in motion; examples include Pfizer and BioNTech, which have already established a strategic partnership in mRNA technology discovery, and AstraZeneca and Huma, which are collaborating to scale innovation for digital health. These partnerships are indicative of increasing collaborations throughout the industry across functions.

Automation, centralization, and new job requirements may affect nearly 90 percent of today’s workforce, and to deal with this challenge, companies could adopt effective long-term strategies. Retaining talent is challenging in the present environment, with the share of workers planning to leave their jobs in the next three to six months standing at 40 percent since 2021 . 1 Aaron De Smet, Bonnie Dowling, Bryan Hancock, and Bill Schaninger, “ The Great Attrition is making hiring harder. Are you searching the right talent pool? ” July 13, 2022. Strategies for talent retention should therefore be broad and focus on more than just salary.

A viable long-term solution to talent shortages may need to involve more than increasing wages to attract people. To solve structural talent gaps, companies could ensure long-term reskilling and upskilling of the existing workforce. For example, Roche runs an operations rotational program to attract top talent with bachelor’s and master’s degrees, and early in the COVID-19 pandemic, Novartis launched a “choice with responsibility” policy to improve overall employee experience.

Successfully developing a robust operations strategy is complex and requires dedicated resources with the ability to focus on the medium to long term. This means the C-suite will need to prioritize efforts and provide adequate resourcing. Only the CEO and head of operations can set the appropriate direction for their organization, steer their company’s effort, gather the right skills and teams, and manage complex interdependencies and resource-intensive interventions.

Are companies doing enough?

As COOs look to emerge from the disruption of the past two years, reflecting on several questions could help them evaluate their organizations’ level of preparedness to respond to the trends affecting the industry. The process could provide foundational answers to inform a renewed operations strategy.

• Have you projected the impact of today’s current trends on your business?
• Do you have a focused, skilled, and scaled operations strategy team that identifies, prioritizes, and deploys initiatives across different horizons?
• Are your resilience measures proactive and dynamic, and are they being built on talent and digital capabilities to achieve greater agility and reliability?
• Have you experienced greater access to innovation and flexibility as a result of expanding your services and strategic partnerships?
• Has your digital strategy created benefits across your network and transformed your operation from digitally enabled to digitally driven?
• Have you achieved ESG improvements, and do you have a broad, long-term road map for ESG commitments (beyond net zero)?
• Has your operating model been agile enough to adapt to rapidly changing operations requirements, such as new modalities and potential disruptions?
• Have you successfully transformed your operations workforce and comprehensively improved the employee experience?
• Do you have an established governance process that incorporates past lessons into future strategy?

Although the pharma industry has performed a remarkable feat in delivering COVID-19 vaccines while also meeting growing demand, current trends create a challenging environment for pharma­ceutical companies. Companies face greater costs, complexity, and risk.

Now is the time to rethink operational strategy to respond to these trends and remain competitive. Such change may have associated challenges and will require bold and innovative leadership. But if companies successfully implement new strategies, they could position themselves to take advantage of the industry’s remarkable growth.

Hillary Dukart is an associate partner in McKinsey’s Denver office, Laurie Lanoue is a partner in the Montreal office, Mariel Rezende is a consultant in the Miami office, and Paul Rutten is a partner in the Amsterdam office.

The authors wish to thank Joe Hughes and Jean-Baptiste Pelletier for their contributions to this article.

Explore a career with us

Related articles.

Against the odds: How life sciences companies excel in large transformations

Four ways to make sure your pharma manufacturing strategy delivers value

Operations can launch the next blockbuster in pharma

/ Article

Building effective business development in pharma.

By  Mark Lubkeman ,  André Kronimus , and  Filip Hansen

At a time of rapidly evolving scientific breakthroughs and, coincidentally, of the expiration of many blockbuster drug patents, the key to innovation and revenue growth is pharmaceutical business development. While some innovation and new revenue can come from internal pipelines and assets, business development teams are under intense pressure at most companies to supplement internal efforts with external licensing agreements and M&A. Unfortunately, those teams are frequently unable to deliver the transactions needed for innovation and growth.

Often a major reason for this shortfall is that executive team members are not fully aligned on the role of business development in achieving the company’s strategic priorities. They may agree in theory that business development should pursue partnerships, ecosystems, and collaborations, but that consensus falls apart when it comes to making decisions about specific deals.

We have identified six success factors that enable more rapid and effective decision making, which, in turn, will lead to substantially enhanced business development performance.

Subscribe to our Biopharma E-Alert.

Biopharma m&a and licensing remain strong.

Biopharma M&A deal value more than doubled between 2017 and 2019, from $138 billion to $336 billion, and valuations reached all-time highs. Most of those deals involved midsized biotech companies, for which the average premium paid was close to 70%, with an average EV/sales multiple of nearly 8x. All in all, close to 60% of new therapeutic drugs in the last five years have been externally sourced.

The COVID-19 pandemic slowed biopharma M&A activity in 2020, especially in the first half of the year. But since the core drivers of deals remain intact—scientific breakthroughs, expiring patents, and an increasing focus on key therapeutic areas or on modalities such as cell and gene therapy—deal activity will continue to rebound. A recent example is AstraZeneca’s acquisition in late December of Alexion for $39 billion.

Moreover, biopharma companies can finance transactions cheaply with today’s very low interest rates. They also have significant financial resources to pursue business development. BCG’s ValueScience team estimates that the top 20 biopharma companies have more than $700 billion in cash, short-term investments, and additional debt capacity. But as a result, many companies are pursuing the same assets, driving up valuations and the risk of overpaying.

Six Success Factors for Pharma Business Development While we focus here on M&A, the six success factors we have identified will enable business development teams to create value through both M&A and licensing. (See Exhibit 1.)

1. Prioritize what business development needs to accomplish for the company. Executive team members often have differing views about how to prioritize business units, technology areas, and technology platforms and what types of deals to pursue (early- versus late-stage R&D deals, for example, or transformative versus tuck-in acquisitions). To ensure alignment, it’s critical that team members agree on how and where they want to create value. Will they use business development to generate near-term revenues or to build the pipeline for future innovation? Will they seek to maximize the core, expand into adjacent markets, or explore new frontiers? (See Exhibit 2.)

As part of this prioritization process, the executive team needs to regularly review and agree on how much revenue growth the current internal portfolio or pipeline will deliver. Only then can it determine the revenue gaps that business development needs to address in which specific therapeutic areas or modalities—and with what urgency. It’s astonishing how often management teams are misaligned on this simple setting of objectives, which often results in business development teams wasting time assessing opportunities that are fundamentally unattractive to the executive team and will never get approved. To avoid such situations, the team should ask itself two key questions about every transaction early on: What revenue gap will the transaction fill? And who on the executive committee will champion the transaction from start to finish? By forcing these decisions early, the team can avoid a lot of wasted time.

2. Build relationships with prospective targets. Executive teams should commit to building relationships with potential partners or acquisition targets for two or three years. Proactive sourcing, screening, and relationship building are far better for deal execution than simply showing up at the target’s headquarters with a banker and an offer. An established relationship will give a prospective buyer an edge over other bidders, perhaps even preempting the bidding process altogether. Such relationships can also accelerate due diligence.

Active engagement with potential targets over several years also gives companies a better grasp of the range of potential deals available. It might, for example, make a pharmaceutical company more likely to take small equity stakes in a number of promising biotechs, perhaps supporting Phase 1 trials with its own clinical and regulatory expertise.

3. Agree on how to assess value. Depending on one’s assumptions when valuing a target, the same transaction may seem spectacularly attractive or exceptionally unattractive. So teams need to agree about how they will value all aspects of each deal and then apply that valuation with discipline. Too often, companies end up redoing their analysis and engaging in repetitive decision making because they haven’t agreed on valuation approaches or metrics from the start.

One common valuation pitfall is to focus only on core asset value, that is, the value of the cash flow generated by current and future products in the market. Valuation models need a wider lens, encompassing multiple dimensions of value, including the following:

• Synergies. What is the value of cost, revenue, and capability synergies across the value chain—for example, in R&D, manufacturing, and sales?
• Platform Value. What is the value of the future products a technology platform might make possible?
• Strategic Value. What is the value of preempting a competitor from acquiring an asset, gaining access to a large proprietary data set, or being recognized as a leader in an emerging field?

Because these advantages are less tangible than core assets, large swings in valuation are possible depending on the underlying assumptions. We have found that companies with a clearly defined and endorsed valuation approach are able to use a common “language” in their deliberations, leading to better, faster decision making. These advantages are amplified when the company is highly transparent about the underlying assumptions and entertains a range of scenarios and associated probabilities.

4. Define integration issues early. Executive and business development teams are frequently so focused on due diligence and valuation that they don’t consider the integration process until after a term sheet has been signed. Integration issues should be considered at the outset, when assessing the deal’s attractiveness and viability, and in parallel with due diligence. Teams should ask such questions as: Will the acquired company be a distinct entity or be integrated into the acquiring company? What governance will be applied to the acquired assets? How will cost synergies factor into the valuation?

Knowing the answers to these questions early on is critical to realizing the full potential of the transaction. Our research shows that successful integration can drive 8% to 10% more value compared with the average transaction. Planning for that success right from the start is essential.

5. Enable agile business development teaming and governance. Even when a company has a clear vision for the transaction, it still needs an agile process and governance to execute the deal quickly and effectively. But because the business development process is highly cross-functional (and often involves many junior-level people), it can be unclear who has the authority to make decisions and who will provide the necessary analytical resources. In addition, preexisting governance committees (such as executive committees) often meet too infrequently to keep up with the fast pace of business development decision making.

To address these challenges, we recommend three best practices:

• Designate resources. Within each function, several senior staff members with business development experience and authority should be on call. This will help build continuity and organizational learning.
• Establish clear processes and responsibilities. All members of a business development project team should be aligned on processes, deliverables, and timelines. That should include who is responsible for what and who has what decision rights. For example, who in R&D will calculate the probability of success of a specific asset under review?
• Create nimble governance. A few members of key governance committees should meet more frequently than the entire group (perhaps even on a weekly basis, depending on deal volume) and have the authority to mobilize the entire committee within 24 or 48 hours if there’s an urgent issue to be addressed.

6. Design an organizational structure suited to strategic priorities. Because companies have different revenue gaps and objectives and use business development in different ways, there is no single “right” organizational structure. One company might focus on early-stage and another on late-stage acquisitions. One company might be looking for deals to strengthen the core business, another to build up new therapeutic areas. A company’s business development organization must be suited to its strategic purpose, whatever that may be. There are three main approaches (with various permutations) to consider:

• Centralize business development in one group. A central function maximizes scale, alignment of activities, and resource prioritization. This setup works well for companies looking to make relatively few late-stage or transformative acquisitions.
• Separate R&D and commercial transactions. Assessing an early-stage R&D acquisition requires a different mix of expertise than assessing a late-stage, commercial acquisition. When a company intends to pursue both types of transactions, it’s best to keep at least some of these due diligence activities separate. But such companies can still centralize certain functions—valuation modeling, for example—in order to maximize scale.
• Separate by business lines or therapeutic areas. It can be sensible to separate business development activities by business lines or therapeutic areas at different levels of maturity. This arrangement works well if a company has a mature business area looking for transformative deals and a smaller business unit looking for technology platform acquisitions. Here again, certain aspects of the business development process, such as valuation modeling, can be centralized for scale and efficiency.

Current market conditions present unique opportunities to tap into external innovation and drive revenue growth, but the inherently complex and cross-functional nature of business development makes it difficult for many pharmaceutical companies to execute effectively. As a result, these companies are not winning the transactions necessary for future success. We believe that the six success factors described above can significantly improve business development capabilities and are worth serious consideration by management teams.

Managing Director & Senior Partner

ABOUT BOSTON CONSULTING GROUP

Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact.

Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place.

© Boston Consulting Group 2024. All rights reserved.

For information or permission to reprint, please contact BCG at [email protected] . To find the latest BCG content and register to receive e-alerts on this topic or others, please visit bcg.com . Follow Boston Consulting Group on Facebook and X (formerly Twitter) .

What Is Next

Read more insights from BCG’s teams of experts.

Lessons from Successful Serial Acquirers

Successful serial acquirers deliver more growth and create more value from acquisitions than their peers. What explains their success?

Most Tech Deals Focus on Growth. Most Post-Merger Integrations Don’t.

A survey of dealmakers shows that technology companies can maximize the value from M&A by aligning their predeal strategy with their postdeal priorities.

Creating Value from Midsize Biopharma Acquisitions

Although small in scale relative to the acquiring company, midsize acquisitions are becoming important to creating value in the biopharmaceutical industry.

Post-Merger Integration in Retail

How to boost the odds that your M&A deal delivers the value you’re counting on? Start planning early for success—using a proven five-step process.

Pharma Pitch Deck Guide (Approved for Biotech & Health)

May 31, 2024

Presentation and Pitch Expert. Ex Advertising.

$100mill In Funding. Bald Since 2010.

Welcome, pharmaceutical enthusiasts! In the exciting world of pharma, pitching is everything. It’s the difference between getting funding for your groundbreaking medical device or not. But fear not, because we’ve got the prescription for success with this pharma pitch deck guide.

We’ll take you through the crucial components of a pharma pitch deck, including how to explain complex medical concepts in a way that anyone can understand, showcase the benefits of your product, and win over investors, partners, or clients. With this guide, you’ll be well on your way to making a difference in the world of medicine.

Hey. I’m Viktor, a  pitch deck expert ,  creative strategist  and burger afficionado.   I’ve been a pitch deck expert for the past 10 years and helped clients raise millions and win pitches, with my unique approach to creating pitch decks.

So, whether you’re an experienced pharma executive or a fresh-faced researcher with a big idea, get ready to dive into the world of pharma pitching. And don’t forget to take your daily dose of passion and enthusiasm – it’s the key ingredient to a successful pitch!

Book a free personalized pitch deck consultation and save over 20 hours of your time.

Join hundreds of successful entrepreneurs who’ve transformed their pitch decks with my help.

Let me develop an investor ready deck by using my hands-off approach, which includes: market research, copy, design, financials, narrative and strategy.

One week turnaround time.

The least you will get is 10 actionable tips & strategies to own that next presentation, worth $599, for free.

Sustainability and Social Responsibility in Pharmaceutical Pitch Decks

Synthetic biology for sustainable products, what are some insights on successful biotech startups, what is a pharma pitch deck.

A pharma pitch deck is a presentation that pharmaceutical companies use to communicate their research, products, and potential to potential investors, partners, or clients. The pitch deck is a visual aid that accompanies a verbal presentation and is designed to provide a clear and compelling overview of the company’s key points.

What Is The Purpose Of a Pharma Pitch Deck?

The purpose of a pharma pitch deck is to generate interest in the company and its products, as well as to secure funding, partnerships, or new clients. The deck typically includes information on the company’s research and development pipeline, product candidates, clinical trials, regulatory status, market potential, and financials.

Creating a strong pharma pitch deck is critical to the success of a pharmaceutical company, as it can help secure funding and partnerships, as well as attract top talent. The deck should be well-organized, visually engaging, and supported by data and research. It should also be tailored to the audience and emphasize the unique value proposition of the company’s products or services.

How to Create a Pharma Pitch Deck Presentation? The Exact Pharma Pitch Deck Slide Structure You Can Steal And Use

If you’re looking for an exact structure to use for your pharma pitch deck, this template should provide a solid foundation. Remember that the precise order and content may need to be adjusted based on your specific circumstances, but this will give you a strong start:

• Title Slide: Your company’s name, your name and position, and your contact information.
• Elevator Pitch: A concise, 1-2 sentence description of your company and its value proposition.
• Problem Statement: A clear articulation of the problem your company is aiming to solve, with supporting data if possible.
• Solution : A description of your product or service, and how it solves the identified problem.
• Product/Technology Details: A deeper dive into how your product or technology works. This could include details on the science behind your drug, how it’s administered, and its mechanism of action.
• Clinical Trials and Regulatory Pathway: Details on any completed or planned clinical trials, including results if available. Also, outline your plan for regulatory approval.
• Market Analysis: An overview of your target market, including size, growth rate, and key trends. Include TAM, SAM, and SOM.
• Competitive Analysis: Identify your main competitors and their offerings, and explain what makes your solution unique or better.
• Business Model: Explain how your company will generate revenue. This could be through direct sales, partnerships, licensing, etc.
• Go-to-Market Strategy: Outline your sales and marketing strategy, including key channels and partnerships.
• Financial Projections: Provide a snapshot of your financial projections for the next 3-5 years. 
• Funding Request: If you’re seeking funding, detail how much you need, what it will be used for, and what investors can expect in return.
• Management Team: Highlight the key members of your team and their qualifications. 
• Advisory Board/Key Partnerships: If applicable, mention your advisory board members or key partnerships that add credibility to your company.
• Exit Strategy: Discuss potential exit strategies for investors.
• Thank You/Contact Slide: Wrap up your presentation with a thank you, and reiterate your contact information.

Remember, a pitch deck is not just about providing information—it’s also about telling a compelling story. Make sure your slides flow logically from one to the next, building a persuasive narrative about why your company is a great investment opportunity. Use visuals whenever possible to make your points more engaging and memorable. And rehearse your presentation until you can deliver it confidently and smoothly.

Get My Template That Helped Companies Win $10mill in Funding

To capture the attention of buyers and investors when pitching a Pharma startup, a strong pitch deck is essential.

Fortunately, creating an effective deck doesn’t have to be a daunting task. The key is to know which slides to include. While there are many templates available on websites like Canva, Slidesgo, and Google Slides, they may not align with your brand. This means you’ll have to spend hours customizing them to fit your brand guidelines.

But there is a better way. My clients have successfully used my written template to create outstanding pharma pitch decks in half the time. By using this template, they were able to design a deck that perfectly reflected their brand and secured funding for their pharma product.

Why is it important to understand your audience when creating a pharma pitch deck?

Understanding your audience when creating a pharma pitch deck is crucial for several reasons:

• Communicating Effectively: Different audiences have different levels of knowledge and familiarity with the pharmaceutical industry, its jargon, and its technical details. Tailoring your message to your audience’s level of understanding ensures that your message will be understood and retained. For example, a pitch to a group of medical professionals might use more technical language than one aimed at generalist investors.
• Highlighting Relevant Information: Depending on who you’re pitching to, different aspects of your business might be more appealing. Investors may be more interested in market size, revenue projections, and exit strategy, while potential partners might be more interested in the specifics of your technology or your regulatory strategy. Understanding your audience allows you to emphasize the most relevant information.
• Addressing Concerns: Different audiences will have different concerns and questions about your business. Potential regulatory issues might be a major concern for industry insiders, while investors might be more worried about the competitive landscape or the scalability of your business model. By understanding your audience, you can anticipate and proactively address these concerns.
• Establishing Credibility: Demonstrating that you understand your audience and their needs helps to establish your credibility. This can be particularly important in the pharmaceutical industry, where trust and credibility are paramount.
• Creating Connection: Understanding your audience helps you to connect with them on a personal level, which can make your pitch more compelling. This could involve relating your company’s mission to issues your audience cares about, or using stories and examples that will resonate with them.

In short, understanding your audience is key to crafting a pitch deck that is clear, persuasive, and effective.

Why is it important to craft a compelling story when creating a pharma pitch deck?

Creating a compelling story when making a pharma pitch deck is important for several reasons:

• Emotional Engagement: Stories emotionally engage an audience in a way that raw data cannot. When you wrap your company’s mission, product, and strategy in a narrative, it becomes more relatable and memorable. 
• Simplifying Complex Ideas: The pharmaceutical industry is filled with complex concepts and technical jargon. A well-crafted story can help simplify these complexities and make your product or service more understandable to a non-technical audience.
• Highlighting the Journey: A story can illustrate your company’s journey, including the problem you identified, the challenges you’ve faced, and how your solution can bring about meaningful change. This helps to create a fuller picture of your company and its values.
• Differentiation : A compelling narrative can help differentiate your company from competitors. It’s not just about what your product does, but why it matters and how it came to be.
• Building Trust: Sharing your company’s story can build trust with your audience. It shows transparency and gives your audience a glimpse into your company’s culture and values.
• Creating a Connection: A story allows your audience to connect with your company on a personal level. It helps them understand your passion, your commitment, and your vision, which can be incredibly persuasive.
• Guiding the Presentation: A narrative structure can guide your presentation, making it flow smoothly and logically from one point to the next.

Remember, your story should be authentic, engaging, and relevant to your audience. It should highlight the problem you’re solving, why it’s important, and how your solution makes a difference. With a compelling story, you can make your pitch deck not just informative, but memorable and persuasive.

How important are design and visuals when creating a pharma pitch deck?

Design and visuals are extremely important when creating a pharma pitch deck. Here’s why:

• Simplification of Complex Information: The pharmaceutical industry often involves complex concepts, data, and processes. Visuals can help simplify and clarify these complexities, making it easier for your audience to understand your message. For instance, infographics, diagrams, and flowcharts can be used to explain the mechanism of action of a drug or the stages of clinical trials.
• Attention and Engagement: Good design and appealing visuals can capture your audience’s attention and keep them engaged throughout your presentation. This is especially important in longer presentations, where audience attention can start to wane.
• Memory and Recall: People generally remember visual information better than verbal or written information. By incorporating visuals into your pitch deck, you’re making your message more memorable.
• Professionalism and Credibility: A well-designed pitch deck gives the impression of professionalism and can enhance your credibility. Conversely, a poorly designed pitch deck can make your company seem amateurish, regardless of the quality of your content.
• Emotional Impact: Visuals can create an emotional impact that words alone often can’t. This can be especially useful in the pharmaceutical industry, where you might be dealing with issues related to health and wellbeing.

When creating your pitch deck, consider hiring a professional designer if you don’t have the necessary skills in-house. Also, remember that while visuals are important, they should not be overly complicated or distract from your main message. Use them to enhance and clarify your message, not to confuse or overwhelm your audience.

How to prepare for questions and objections when presenting a pharma pitch deck?

Preparing for questions and objections is an essential part of any pitch presentation. Here’s how you can prepare for these when presenting a pharma pitch deck:

• Anticipate Common Questions: Based on your knowledge of the industry and your specific product or service, anticipate the questions that are likely to come up. These might involve details about your drug’s mechanism of action, your clinical trial results, your regulatory strategy, or your financial projections. Prepare clear, concise responses to these questions.
• Understand Potential Objections: Think about the potential objections that could be raised. These might be concerns about the competitive landscape, the scalability of your business model, potential regulatory hurdles, or the risks and uncertainties associated with drug development. Prepare responses that address these objections head-on and that highlight your strategies for managing these risks.
• Know Your Data: Be intimately familiar with all the data in your pitch deck, as well as any additional data that supports your claims. This might include detailed clinical trial results, market research data, or financial forecasts. Being able to quickly reference and explain this data will help you respond confidently to questions.
• Practice, Practice, Practice: The more you practice your presentation and your responses to potential questions and objections, the more comfortable and confident you’ll be. Consider doing a mock presentation with colleagues or mentors and ask them to challenge you with tough questions.
• Stay Current: Keep up-to-date with the latest developments in your industry and any news or events that might impact your business. This will allow you to address any topical questions or concerns.
• Maintain a Positive Attitude: Regardless of the question or objection, maintain a positive and open attitude. Remember that questions are an opportunity to provide more information and build confidence in your company.
• Don’t Guess or Make Up Answers: If you don’t know the answer to a question, it’s better to admit it and offer to follow up later than to guess or make up an answer. Maintaining credibility is crucial.

Remember, while you can’t anticipate every question or objection, being well-prepared will help you handle whatever comes your way with confidence and poise.

What nobody will tell you: Crucial considerations to keep in mind when developing your pharma pitch deck and business

10 insights. These are things no advisor, startup event organizer or coach will tell you for free. We’ve done the research and combined it with our experience to give you these insights with no strings attached.

Market Analysis and Trends in Pharmaceutical Industry for Pitch Deck Development

Importance of Market Analysis and Trends in Pharma Pitch Decks: Market Analysis and Trends are crucial in a pharmaceutical pitch deck as they provide a clear understanding of the current market scenario, potential growth areas, and competitive landscape. This insight is essential for convincing investors and stakeholders that your idea or product has a viable place in the market.

Specific Research and Insights:

• Evolving Disease Profiles: Highlight current research on emerging diseases and shifts in global health patterns. For instance, the rise in chronic diseases like diabetes or the emergence of new viral threats.
• Technological Advancements: Focus on cutting-edge technologies such as CRISPR, AI in drug discovery, and telemedicine, and how they are reshaping the industry.
• Regulatory Changes: Update on recent FDA regulations, global healthcare policies, and their impact on pharmaceutical companies.
• Market Size and Forecast: Provide statistics on the size of the pharmaceutical market and forecasted growth, segmented by regions, product types, or therapeutic areas.
• Consumer Behavior: Insights into patient preferences, drug adherence patterns, and the shift towards personalized medicine.

Actions to Take for Incorporating Market Analysis into a Pharma Pitch Deck:

• Conduct Comprehensive Research: Utilize reputable sources like WHO reports, pharmaceutical market analysis from firms like McKinsey & Company or Deloitte, and scientific publications for the latest data and trends.
• Identify Niche Markets: Based on the research, identify niche markets or unmet medical needs your product or idea can address. This shows potential for growth and opportunity.
• Benchmark Against Competitors: Analyze key competitors in your target market. Highlight your unique value proposition compared to existing solutions.
• Integrate Real-World Data: Use case studies or real-world examples to demonstrate how trends are impacting the industry and how your product fits into this evolving landscape.
• Future Outlook: Discuss how ongoing trends will shape the future of the market and how your product is positioned to evolve with these changes.
• Create Visual Representations: Develop charts, graphs, and infographics to visually represent market trends and data. This makes your pitch deck more engaging and easier to understand.
• Customize for Your Audience: Tailor the market analysis to reflect the interests and concerns of your specific audience, whether they are investors, partners, or other stakeholders.

By focusing on these areas, your pharma pitch deck will not only be well-researched and informative but also demonstrate a deep understanding of the market dynamics, increasing its effectiveness in attracting investment and support.

Regulatory Compliance and Approval Processes in Pharmaceutical Industry for Pitch Deck Development

Importance of Regulatory Compliance and Approval Processes in Pharma Pitch Decks: Understanding and effectively communicating regulatory compliance and approval processes is vital in a pharmaceutical pitch deck. It assures potential investors and stakeholders that the product or service is not only innovative but also aligns with the stringent regulatory standards of the industry. This understanding mitigates risk and demonstrates the feasibility and longevity of the product in the market.

• FDA Approval Process: Detail the steps involved in obtaining FDA approval, including preclinical research, clinical trials (Phases I-IV), and the New Drug Application (NDA) process.
• Global Regulatory Variations: Address the differences in regulatory processes across key markets like the EMA (European Medicines Agency) and other national bodies.
• Compliance Challenges: Discuss common compliance challenges and how your product is designed to navigate these effectively.
• Recent Regulatory Changes: Include recent changes or updates in regulatory policies that could impact the development and marketing of pharmaceutical products.

Actions to Take for Incorporating Regulatory Insights into a Pharma Pitch Deck:

• Gather Accurate Information: Utilize resources from the FDA, EMA, and other regulatory bodies. Stay updated with publications and reports from regulatory experts and pharmaceutical consultants.
• Consult Regulatory Experts: Engage with regulatory affairs professionals to ensure that your pitch deck reflects a thorough understanding of the necessary compliance processes.
• Risk Assessment: Analyze and present potential regulatory risks and your strategies to mitigate them. This shows foresight and preparedness.
• Timeline and Milestones: Create a clear timeline of the expected regulatory process, including key milestones. This helps in setting realistic expectations for product development and market entry.
• Case Studies of Regulatory Success: Incorporate case studies of pharmaceutical products that have successfully navigated the regulatory landscape. This can serve as a proof of concept and inspire confidence.
• Customize for Specific Products: Tailor the regulatory information based on the type of pharmaceutical product (e.g., biologics, small molecules, medical devices) as each category has different regulatory pathways.
• Visual Aids: Use flowcharts or diagrams to simplify complex regulatory processes, making them easier for your audience to comprehend.
• Link Regulatory Strategy to Business Goals: Demonstrate how your regulatory strategy aligns with and supports your overall business objectives.

By integrating these elements into your pitch deck, you’ll be able to effectively communicate the importance of regulatory compliance and approval processes, showcasing not just the innovation behind your product, but also its practical viability and market readiness.

Innovation in Drug Discovery and Development for Pharmaceutical Pitch Decks

Importance of Innovation in Drug Discovery and Development in Pharma Pitch Decks: In the pharmaceutical industry, innovation in drug discovery and development is a key driver of success. Highlighting innovation in your pitch deck not only showcases your product’s unique value proposition but also demonstrates your commitment to addressing unmet medical needs with cutting-edge solutions. This aspect is crucial for attracting investors who are looking for opportunities that have the potential to disrupt the market and offer significant returns.

• Latest Drug Discovery Techniques: Research on advanced methodologies like AI-driven drug discovery, high-throughput screening, and genomics.
• Breakthrough Treatments: Information on recent breakthrough treatments, especially in areas like oncology, rare diseases, and personalized medicine.
• Clinical Trial Innovations: Developments in clinical trial designs, such as adaptive trials or the use of real-world evidence.
• Collaboration and Partnerships: Trends in strategic partnerships and collaborations that accelerate drug development processes.

Actions to Take for Incorporating Innovation into a Pharma Pitch Deck:

• Showcase Cutting-Edge Research: Present the latest research and technologies you are utilizing in your drug discovery and development processes. Use reputable sources like scientific journals and industry reports.
• Emphasize Unique Aspects: Clearly articulate what sets your innovation apart from existing solutions. This could be a novel mechanism of action, faster development times, or more effective treatment outcomes.
• Clinical Trial Data: If available, include promising data from preclinical studies or clinical trials that underscore the efficacy and safety of your innovation.
• Highlight Intellectual Property: Discuss patents or proprietary technology that protect your innovation, reinforcing its market value and potential for return on investment.
• Address Market Needs: Connect your innovation to specific unmet needs in the market, demonstrating your understanding of the industry landscape and patient requirements.
• Use Visuals and Infographics: Employ visuals to explain complex scientific concepts. Infographics and diagrams can make your innovation more accessible to a non-specialist audience.
• Discuss Scalability and Manufacturing: Outline your plans for scaling up production and distribution, showing that you have a feasible roadmap for bringing your innovation to market.
• Tailor Content for Audience: Adapt the level of technical detail based on your audience’s familiarity with pharmaceutical research and development.

By incorporating these elements, your pitch deck will not only highlight the innovative aspects of your drug discovery and development but also build a compelling case for the investment, showcasing the potential impact and profitability of your pharmaceutical product.

Investor and Funding Insights for Pharmaceutical Pitch Decks

Importance of Investor and Funding Insights in Pharma Pitch Decks: In a pharmaceutical pitch deck, understanding the investor landscape and funding mechanisms is critical. It’s not just about showcasing your product or innovation; it’s also about demonstrating how you align with the financial expectations and strategic interests of potential investors. Presenting clear, well-researched funding insights shows that you are not only a scientific innovator but also a savvy business thinker.

• Investor Profiles: Research on the types of investors interested in pharmaceutical ventures, such as venture capitalists, angel investors, pharmaceutical corporations, and government grants.
• Investment Trends: Insights into current investment trends in the pharmaceutical sector, including areas of high interest like biotechnology, digital health, and personalized medicine.
• Funding Case Studies: Analysis of recent successful funding rounds in the pharmaceutical industry, highlighting key factors that attracted investors.
• ROI Expectations: Understanding the return on investment (ROI) expectations and timelines typical for pharmaceutical investments.

Actions to Take for Incorporating Investor and Funding Insights into a Pharma Pitch Deck:

• Identify the Right Investors: Research and identify potential investors who have a history of investing in pharmaceutical projects, especially those that align with your specific niche.
• Tailor Your Pitch: Customize your pitch deck to resonate with the specific interests and investment philosophy of the investors you are targeting.
• Highlight Financial Viability: Include detailed financial projections, break-even analysis, and potential profitability. This shows that you understand the financial aspects of bringing a pharmaceutical product to market.
• Discuss Funding Stages: Clearly outline the various stages of funding you’ll need, what each stage will achieve, and how it contributes to the overall development and commercialization of the product.
• Showcase Your Team: Emphasize the expertise and track record of your team, as investors often invest in people as much as in ideas.
• Use Success Stories for Credibility: Incorporate case studies or examples of similar companies that have successfully navigated the funding landscape. This adds credibility to your pitch.
• Detail Use of Funds: Be specific about how you intend to use the funding. Investors want to see that their money will be used efficiently and effectively.
• Prepare for Due Diligence: Anticipate and prepare for the due diligence process. Have all necessary documentation, data, and information ready to demonstrate your thoroughness and professionalism.

By effectively integrating these insights into your pitch deck, you’ll be able to present a compelling and persuasive case to potential investors, showcasing not only the scientific merit of your pharmaceutical innovation but also its potential for financial success and growth.

Intellectual Property and Patent Strategies for Pharmaceutical Pitch Decks

Importance of Intellectual Property and Patent Strategies in Pharma Pitch Decks: In the pharmaceutical industry, where research and development are pivotal, the role of intellectual property (IP) and patent strategies cannot be overstated. For a pitch deck, detailing your approach to IP protection not only safeguards your innovations but also significantly enhances your venture’s attractiveness to investors. Demonstrating a clear, strategic approach to IP and patents signifies that your business is built on a solid foundation with a competitive edge and a clear path to market exclusivity.

• Patent Landscape: Understanding the current patent landscape in your specific pharmaceutical field, including key patents and their holders.
• Patent Life Cycle Management: Strategies for extending the commercial life of a drug, such as formulation patents, method-of-use patents, and strategic patent filings.
• Global IP Considerations: The importance of securing IP rights in different markets, especially considering the variation in patent laws across countries.
• IP as a Business Asset: Viewing IP not just as legal protection but as a core business asset that can be leveraged for funding, partnerships, and market positioning.

Actions to Take for Incorporating IP and Patent Strategies into a Pharma Pitch Deck:

• Conduct a Thorough IP Audit: Begin by conducting a comprehensive audit of your existing and potential IP assets. This should include patent searches to ensure novelty and to avoid infringement.
• Develop a Clear IP Strategy: Articulate a clear strategy for protecting your IP. This may include filing for patents, maintaining trade secrets, or a combination of both.
• Highlight Patent Status: Clearly state the status of your patents (pending, granted) and the geographical coverage. If you have a patent pending, explain the steps being taken towards securing it.
• Explain Patent Strategy’s Role in Business Plan: Illustrate how your patent strategy aligns with and supports your overall business plan and market entry strategy.
• Address Freedom to Operate: Include a freedom-to-operate analysis, showing that your development and commercialization plans do not infringe on others’ IP rights.
• Discuss Future IP Plans: Outline future plans for IP, such as additional filings, international expansions, or strategies for defending your IP rights.
• Showcase Competitive Edge: Use your IP position to highlight your competitive edge in the market. This can include exclusivity in a certain therapeutic area or a novel drug delivery system.
• Prepare for Investor Due Diligence: Be prepared for potential investor due diligence on your IP portfolio. This includes having detailed records and documentation of your IP strategy and filings.

By effectively presenting your intellectual property and patent strategy in your pitch deck, you’re not just showcasing your innovation’s uniqueness, but you’re also demonstrating a strategic approach to market protection and value creation, which is crucial for attracting savvy investors in the pharmaceutical sector.

Case Studies of Successful Pharma Startups for Pitch Decks

Importance of Case Studies in Pharma Pitch Decks: Incorporating case studies of successful pharmaceutical startups in your pitch deck serves multiple purposes. It provides real-world evidence of success, illustrates the practical application of strategies, and inspires confidence in potential investors. Case studies can demonstrate the feasibility of your business model, the effectiveness of your technology, and the potential for market success.

• Success Stories: Research and identify pharmaceutical startups that have successfully brought a product to market, secured significant funding, or achieved a noteworthy milestone (like FDA approval).
• Strategic Moves: Analyze the key strategic decisions that contributed to these startups’ success, such as unique marketing approaches, innovative research methodologies, or effective regulatory navigation.
• Challenges and Solutions: Document the challenges these startups faced and how they overcame them. This could include overcoming regulatory hurdles, solving complex R&D problems, or securing funding in a competitive environment.

Actions to Take for Incorporating Case Studies into a Pharma Pitch Deck:

• Select Relevant Case Studies: Choose case studies that are relevant to your startup in terms of product type, target market, or the challenges you are facing. This relevance makes the case studies more impactful for your audience.
• Highlight Key Learnings: Extract and emphasize the key learnings from each case study. Explain how these learnings have influenced your business strategy and decision-making process.
• Show Parallel Paths: Draw parallels between these successful startups and your company, highlighting similarities in approach, market, or technology.
• Use Data to Support Claims: Where possible, use quantitative data to support the success stories. This could include funding amounts, market share, revenue growth, or clinical trial results.
• Visual Storytelling: Use visuals like timelines, growth charts, or infographics to make the case studies engaging and easy to understand.
• Discuss Adaptation and Improvement: Explain how your strategy adapts or improves upon the strategies used by the case study companies. This demonstrates innovation and forward-thinking.
• Prepare for Questions: Anticipate and prepare for potential questions or skepticism from investors regarding the applicability of these case studies to your venture.
• Cite Sources: Ensure that all case studies are well-cited from credible sources. This adds legitimacy to your pitch and demonstrates thorough research.

By incorporating well-researched and relevant case studies into your pharmaceutical pitch deck, you can effectively showcase the potential for success in your venture. These real-world examples serve as powerful tools for building credibility, illustrating market opportunities, and reinforcing the feasibility of your proposed strategies.

Patient-Centric Approaches in Pharmaceutical Pitch Decks

Importance of Patient-Centric Approaches in Pharma Pitch Decks: Emphasizing patient-centric approaches in your pharmaceutical pitch deck is crucial for demonstrating alignment with current healthcare trends and patient needs. This approach reflects a deep understanding of the end-users — the patients — and their experiences. It shows that your product or service is designed not just from a scientific or commercial perspective, but with a focus on improving patient outcomes, adherence, and satisfaction, which is increasingly important in the healthcare sector.

• Patient Engagement Strategies: Research on effective patient engagement strategies, such as personalized medicine, patient support programs, and digital health tools.
• Impact on Clinical Outcomes: Studies showing how patient-centric approaches can lead to improved clinical outcomes, higher medication adherence, and better overall health.
• Market Demand for Patient-Centric Solutions: Analysis of market trends indicating a growing demand for patient-centric solutions in healthcare.

Actions to Take for Incorporating Patient-Centric Approaches into a Pharma Pitch Deck:

• Highlight Patient Insights: Include research or data that provide insights into patient needs, preferences, and behaviors related to your product.
• Showcase Patient Engagement Tools: If applicable, showcase any patient engagement tools or technologies you are using or developing, such as mobile apps for medication tracking or patient education platforms.
• Demonstrate Impact on Patient Outcomes: Use data or case studies to demonstrate how your product or service positively impacts patient outcomes. This can include clinical trial results, patient testimonials, or real-world evidence.
• Patient-Centric Design and Development: Discuss how patient feedback and insights have been integrated into the design and development of your product. This could include patient advisory boards or user testing results.
• Customize Solutions for Different Patient Groups: Address how your product meets the needs of different patient demographics, such as age groups, disease stages, or specific patient communities.
• Health Economics and Outcomes Research (HEOR): Present any HEOR data that supports the value proposition of your patient-centric approach, such as cost-effectiveness or quality-of-life improvements.
• Collaboration with Patient Groups: If relevant, mention any collaborations or partnerships with patient advocacy groups or healthcare providers focused on patient care.
• Regulatory Considerations: Discuss how your patient-centric approach aligns with regulatory guidelines or has been received by regulatory bodies.

Incorporating patient-centric approaches into your pharmaceutical pitch deck not only shows that your company is aligned with the latest trends in healthcare but also demonstrates a commitment to improving the lives of patients. This approach can significantly enhance the appeal of your pitch to investors and stakeholders who are increasingly looking for solutions that offer tangible benefits to patients.

Cost Analysis and Pricing Strategies for Pharmaceutical Pitch Decks

Importance of Cost Analysis and Pricing Strategies in Pharma Pitch Decks: Incorporating a detailed cost analysis and pricing strategy into a pharmaceutical pitch deck is essential. It demonstrates to investors and stakeholders not only the financial viability of the product but also an understanding of the market dynamics and competitive landscape. Accurate costing and strategic pricing are crucial for maximizing profitability, ensuring market access, and achieving reimbursement from payers.

• Market-Based Pricing Research: Analysis of current market prices for similar drugs, considering factors like therapeutic value, competition, and market demand.
• Cost of Production: Detailed breakdown of the costs involved in manufacturing, including raw materials, labor, and overheads.
• Regulatory and Clinical Trial Costs: Insights into the costs associated with regulatory compliance and conducting clinical trials.
• Reimbursement Landscape: Understanding of reimbursement policies and pricing thresholds set by insurers and healthcare systems.

Actions to Take for Incorporating Cost Analysis and Pricing Strategies into a Pharma Pitch Deck:

• Conduct Thorough Market Research: Perform comprehensive market research to understand the pricing strategies of competitors and similar products.
• Detail Cost Breakdown: Provide a clear and detailed breakdown of all costs involved in bringing the product to market, including R&D, manufacturing, marketing, and distribution.
• Develop a Pricing Model: Create a well-reasoned pricing model that takes into account production costs, market conditions, competitive analysis, and potential profit margins.
• Address Affordability and Access: Discuss strategies for making the product affordable and accessible, which could include tiered pricing, patient assistance programs, or partnerships with healthcare providers.
• Present Different Pricing Scenarios: Include different pricing scenarios based on various market conditions and regulatory outcomes to demonstrate flexibility and preparedness.
• Highlight Value Proposition: Emphasize the value proposition of your product, linking the price to the benefits it provides, such as improved efficacy, safety, or convenience.
• Include Payer and Reimbursement Strategy: Outline your strategy for securing reimbursement from insurers and healthcare providers, which is critical for market access.
• Prepare Sensitivity Analysis: Offer a sensitivity analysis to show how changes in cost or market conditions could impact your pricing strategy and profitability.

Incorporating a comprehensive cost analysis and pricing strategy into your pharmaceutical pitch deck shows that you have a realistic and well-planned approach to achieving financial success. This level of detail and strategic thinking can significantly increase the confidence of potential investors in the viability and potential profitability of your product.

Technology Integration in Pharmaceutical Pitch Decks

Importance of Technology Integration in Pharma Pitch Decks: Technology integration in pharmaceutical pitch decks is pivotal for demonstrating innovation and efficiency. It showcases how your product or service leverages the latest technologies to enhance drug discovery, development, or delivery. In an industry increasingly driven by technological advancements, highlighting your tech capabilities can set you apart, showing potential investors your commitment to staying at the forefront of pharmaceutical innovation.

• Emerging Technologies in Pharma: Research into cutting-edge technologies like AI and machine learning for drug discovery, blockchain for supply chain transparency, and advanced data analytics for clinical trials.
• Tech-Driven Efficiency Gains: Studies showing how technology can streamline operations, reduce costs, and accelerate time-to-market.
• Digital Health Trends: Insights into digital health trends, including telehealth, wearables for patient monitoring, and personalized medicine.

Actions to Take for Incorporating Technology into a Pharma Pitch Deck:

• Highlight Specific Technologies Used: Clearly identify the technologies you are using or planning to use, explaining how they contribute to your product’s development or enhance its value proposition.
• Demonstrate the Benefits: Explain the tangible benefits of these technologies, such as improved accuracy in drug targeting, faster development times, or enhanced patient engagement.
• Showcase Technological Expertise: If your team has unique expertise in a certain technological area, highlight this as a competitive advantage.
• Include Tech in the Development Timeline: Show where technology integration impacts your product development timeline, potentially speeding up processes like research, trials, or regulatory approval.
• Discuss Partnerships or Collaborations: If you have partnerships with tech companies or are part of a technology-driven consortium, mention these to strengthen your pitch.
• Provide Evidence of Tech-Driven Success: Where possible, include data or case studies that demonstrate the successful application of technology in similar contexts.
• Address Data Security and Compliance: In the context of digital health data, discuss measures for ensuring data security and regulatory compliance.
• Forecast Future Tech Integrations: Discuss future plans for technology integration, showcasing a roadmap for continuous innovation and improvement.

Integrating technology into your pharmaceutical pitch deck not only highlights your product’s innovative aspects but also demonstrates an understanding of modern tools and methods that can streamline development and create more effective, tailored solutions. This approach is crucial for attracting tech-savvy investors and positioning your company as a forward-thinking player in the pharmaceutical industry.

Importance of Sustainability and Social Responsibility in Pharma Pitch Decks: Incorporating sustainability and social responsibility into your pharmaceutical pitch deck is increasingly important in today’s market. It demonstrates to investors and stakeholders that your company is not only focused on profitability but also committed to ethical practices, environmental stewardship, and positive social impact. This approach can enhance corporate reputation, foster trust with consumers and partners, and align with global trends towards responsible business practices.

• Environmental Impact of Pharma Industry: Data on the environmental footprint of pharmaceutical production, including waste management, carbon emissions, and resource consumption.
• Ethical Supply Chain Management: Research on the importance of ethical sourcing and supply chain transparency in the pharmaceutical industry.
• Corporate Social Responsibility (CSR) Initiatives: Examples of successful CSR initiatives in pharma, such as community health programs, access to medicine in developing countries, and diversity and inclusion efforts.

Actions to Take for Incorporating Sustainability and Social Responsibility into a Pharma Pitch Deck:

• Articulate Your Commitment: Clearly state your company’s commitment to sustainability and social responsibility, outlining your guiding principles and goals.
• Showcase Sustainable Practices: Highlight specific sustainable practices your company has implemented or plans to implement, such as eco-friendly manufacturing processes, renewable energy use, or water conservation efforts.
• Discuss Ethical Sourcing: Explain how your company ensures ethical sourcing of raw materials, potentially including supplier audits and adherence to international standards.
• Highlight Social Initiatives: Share any social initiatives your company is involved in, such as disease awareness campaigns, community healthcare projects, or partnerships with non-profits.
• Demonstrate Compliance with Regulations: Ensure and demonstrate compliance with environmental and social regulations relevant to the pharmaceutical industry.
• Report on Sustainability Metrics: Include metrics or targets related to sustainability, such as reduced carbon footprint, waste reduction goals, or community impact measures.
• Incorporate Sustainable Innovation: Discuss how innovation in your company contributes to sustainable healthcare solutions, like developing drugs with lower environmental impact or more efficient delivery methods.
• Align with Global Sustainability Goals: Align your sustainability and social responsibility strategies with global goals, such as the UN Sustainable Development Goals, to resonate with a global audience.

Incorporating sustainability and social responsibility into your pharmaceutical pitch deck not only positions your company as a modern and ethically conscious player in the industry but also resonates with a growing segment of investors and consumers who prioritize these values. This approach can differentiate your company, build long-term loyalty, and contribute to sustainable growth in the pharmaceutical sector.

Use these insights and make a winning pitch. If you want to talk about them, reach out to me and book a call.

What are the best practices when creating a pharma pitch deck?

Creating a pharmaceutical pitch deck involves a unique blend of scientific information, business strategy, and storytelling. Here are some best practices to keep in mind when creating your pitch deck:

• Know Your Audience: Tailor your presentation to the knowledge level, interests, and concerns of your audience. A pitch to a group of medical professionals might look very different from one to generalist investors.
• Simplify Complex Information: The pharmaceutical industry can be complex and filled with jargon. Make sure your message is clear and understandable to your intended audience. Use visuals and analogies to simplify complex concepts.
• Tell a Compelling Story: Create a narrative around your company and its mission. Highlight the problem you’re addressing, why it’s important, and how your solution can bring about meaningful change. If you want to enhance your storytelling skills, take a look at this compilation of best books for pitching . These authors have earned billions of dollars by crafting compelling narratives during their pitches and are now revealing their techniques to you.
• Use Visuals Effectively: Use visuals to enhance and clarify your message, not to overwhelm or confuse your audience. Infographics, diagrams, and charts can be used to represent complex data or processes.
• Highlight Your Unique Value Proposition: Clearly articulate what sets your company apart from the competition. This could be your technology, your team, your strategy, or a combination of factors.
• Show Evidence of Progress: Show evidence of your progress, such as results from clinical trials, regulatory approvals, or key partnerships. This can give your audience confidence in your ability to execute your plans.
• Be Transparent About Risks and Challenges: Every pharmaceutical venture has risks and challenges, whether it’s regulatory hurdles, clinical trial uncertainties, or competitive threats. Be transparent about these, but also show how you’re managing them.
• Practice Your Presentation: Rehearse your presentation until you can deliver it confidently and smoothly. Be prepared to answer questions and handle objections.
• Keep it Concise: Respect your audience’s time by keeping your presentation concise. Aim for around 15-20 slides and try to keep your presentation under 20 minutes.
• Proofread : Ensure your pitch deck is free of typos and errors, which can detract from your credibility.

Remember, your pitch deck is not just about providing information—it’s also about creating a persuasive narrative that inspires your audience to take action.

Hold on. You might want to check my list on the best presentation books. Why?

It’s 1O crucial books that will help you improve the design and structure of your presentations, besides improving its delivery. Check it out below.

How to creatively pitch your pharma startup?

Pitching a pharmaceutical startup requires a blend of scientific credibility and creative flair to capture and maintain the attention of your audience. Here are some novel and engaging ideas to consider when presenting your pharma pitch deck on stage:

• Interactive Virtual Reality Experience: Create a virtual reality (VR) experience that takes investors inside the human body to show how your drug or technology works. This immersive experience can provide a unique perspective and make complex scientific concepts more tangible and engaging.
• Live Demonstration with Wearable Tech: If your product involves wearable technology or patient monitoring devices, conduct a live demonstration. Show real-time data and how your technology interacts with users, providing a practical demonstration of its benefits.
• Dramatized Patient Journey: Use actors to enact a patient’s journey, from diagnosis to treatment using your product. This storytelling approach can emotionally connect the audience with the patient’s challenges and the solutions your product offers.
• Augmented Reality Data Visualization: Use augmented reality (AR) to visualize complex data, such as clinical trial results or market analysis. AR can make data more interactive and engaging, allowing you to highlight key points effectively.
• Science Meets Art Installation: Create an art installation that represents the science behind your product. For example, a sculpture or visual art piece that symbolizes the mechanism of your drug at a molecular level. This fusion of art and science can be both eye-catching and informative.
• Gamification of Your Pitch: Turn aspects of your pitch into an interactive game. For instance, have the audience participate in a quiz or a puzzle that reveals information about your product, market, or technology.
• ‘Day in the Life’ Simulation: Set up a simulation that allows audience members to experience a ‘day in the life’ of a patient or healthcare provider who would use your product. This can foster empathy and a deeper understanding of the need for your solution.
• Flash Mob or Performative Element: Begin your presentation with a flash mob or a short performance that metaphorically represents the problem your product solves or the journey of bringing your product to market.
• Personal Storytelling: Share a personal story or testimonial that inspired your pharmaceutical product. A compelling narrative can create an emotional connection and make your presentation memorable.
• Use of Holograms for Demonstrations: If feasible, use holographic technology to demonstrate your product or to visualize its impact. This high-tech approach can be particularly engaging and memorable.
• 3D Printed Models: Bring 3D printed models of molecules, compounds, or even the drug delivery system. Physical models can make abstract concepts more concrete and accessible.
• Interactive Polls or Surveys: Use real-time interactive polls or surveys with the audience to engage them and gather instant feedback or opinions related to your presentation or product.
• Time Capsule Concept: Present your pitch as a journey through time. Start with the past (the current problems in healthcare), navigate through the present (how your product addresses these issues), and project into the future (the potential long-term impact of your solution). This can be visualized through a creative set design or multimedia presentation.
• Interactive Lab Setup: Transform the stage into a mock laboratory, where you can demonstrate some basic science related to your product. This could involve simple, safe experiments or demonstrations that metaphorically represent your product’s functionality.
• Patient Testimonials via Hologram: Use holographic technology to project testimonials from patients or healthcare providers who have benefited from your product or a similar solution. This high-tech approach can give a powerful and humanizing element to your pitch.
• Themed Costume and Set Design: Dress in a costume that represents a key element of your product or its development journey. Complement this with a set design that immerses the audience in the theme of your presentation.
• Pharma ‘Escape Room’ Challenge: Create an ‘escape room’ style challenge for your audience, where they need to solve puzzles related to healthcare challenges that your product addresses. This interactive approach can be both fun and educational.
• Musical or Dance Interpretation: Incorporate a musical or dance performance that metaphorically tells the story of the problem your product solves or the journey of its development. This can add an artistic and emotional dimension to your pitch.
• ‘Mythbusters’ Style Segment: Debunk common myths or misconceptions in the pharmaceutical industry related to your product area. This can be done in a fun, Mythbusters-style interactive segment.
• Use of Scent and Sensory Elements: If applicable, incorporate sensory elements into your presentation. For example, if your product involves improving patient environments, use pleasant, calming scents in the room to enhance the experience.
• Incorporating Stand-Up Comedy: Lighten the mood and engage the audience with humor related to your field, perhaps through a short stand-up comedy routine that segues into the more serious aspects of your pitch.
• Pharma Fashion Show: If your product involves wearable technology, organize a mini fashion show to showcase how your technology integrates seamlessly into daily life.
• Celebrity Endorsement Video: If possible, include a short endorsement or message from a celebrity or well-known figure in the healthcare field. This can add a surprise element and increase the credibility of your pitch.
• Interactive 3D Mapping: Use 3D projection mapping technology on stage to create an interactive and immersive environment that illustrates the impact of your product in the healthcare sector.

Remember, the goal of these creative approaches is not just to entertain, but to effectively communicate the value and potential of your pharmaceutical product in a way that resonates with your audience.

Pharma Pitch Deck Examples

Alright I got some good ones for you here.

Innovative Drug Delivery Systems

• Problem : The efficacy of drugs can be severely affected by issues in the administration process, such as dosage errors, poor absorption, and patient noncompliance.
• Solution : Our technology uses nanotechnology and smart biosensors to create a unique drug delivery system that enhances absorption and ensures accurate dosing.
• Market Opportunity: This will revolutionize the $300 billion pharmaceutical market, starting with diabetes and cardiovascular medications.
• Business Model: We will collaborate with pharmaceutical companies, licensing our technology for their specific drugs.
• Traction: We have successfully completed preclinical trials and have patents pending for our technology.

Gene Editing for Personalized Medicine

• Problem : Current treatments for genetic disorders are mostly symptomatic, with limited effectiveness.
• Solution : We leverage CRISPR gene-editing technology to create personalized therapies that can modify disease-causing genes.
• Market Opportunity: With millions of people suffering from genetic disorders, the market potential for curative treatments is enormous.
• Business Model: Revenue will be generated from the sales of gene therapies, collaborations with big pharma, and contract research.
• Traction : We have proven the effectiveness of our therapies in vitro and in animal models. Now we are planning our first human trial.

Bioengineered Organ Transplants

• Problem : There is a drastic shortage of organ donors, and many patients die while waiting for a transplant.
• Solution : Using 3D bioprinting technology and stem cells, we create bioengineered organs for transplantation.
• Market Opportunity: There are over 100,000 people on the organ transplant waiting list in the U.S. alone, representing a significant market opportunity.
• Business Model: Revenue will be derived from the sales of bioengineered organs to healthcare institutions.
• Traction : We have successfully bioengineered and transplanted kidneys in small animal models.

AI-Driven Drug Discovery

•   Problem : Traditional drug discovery is costly and time-consuming, often taking years and billions of dollars to bring a drug to market.
• Solution : We use artificial intelligence and machine learning to expedite drug discovery by predicting drug efficacy and safety in the early stages.
• Market Opportunity: The global pharmaceutical market is over a trillion dollars, and our technology can significantly reduce R&D costs and speed up time-to-market.
• Business Model: We will license our AI software to pharmaceutical companies and form strategic partnerships for drug development.
• Traction : Our software has already predicted several potential drug candidates which are now undergoing further laboratory testing.

• Problem : Many consumer products are derived from non-renewable resources, contributing to environmental damage.
• Solution : We use synthetic biology techniques to engineer microorganisms to produce sustainable alternatives to these non-renewable resources, such as bioplastics and biofuels.
• Market Opportunity: As businesses and consumers demand greener products, the potential market for bio-based products is growing rapidly.
• Business Model: We will sell our bio-products to manufacturers and license our technology for mass production.
• Traction : We have successfully produced and tested our first bioplastic prototypes, showing excellent properties comparable to petroleum-based plastics.  

Each of these pitch decks will need a compelling story, details about the team, competitive analysis, go-to-market strategy, and financial projections to complete the picture. These elements are integral in conveying the potential value and viability of the business.

Pitch Decks From Successful Pharma Companies

Questions that investors ask pharma product owners.

When presenting a hedge fund pitch deck to potential investors, be prepared to answer various questions regarding your fund’s strategy, risk management, team, and performance. Here are some common questions investors might ask:

• Investment Strategy: What is your hedge fund’s investment strategy? How do you identify and select investment opportunities? How do you generate alpha?
• Risk Management: What risk management techniques do you employ? How do you measure and monitor risk? What is your approach to managing downside risk and protecting capital?
• Track Record: What is the fund’s historical performance? How has the fund performed in various market conditions, and how does it compare to relevant benchmarks?
• Liquidity : What is the fund’s liquidity profile? How easily can investors redeem their investments? What is the redemption frequency and notice period?
• Fees : What are your management and performance fees? Are there any additional fees investors should be aware of? How do your fees compare to industry standards?
• Fund Structure: What is the legal structure of the fund? Are there any tax implications for investors?
• Portfolio Concentration: What is the typical portfolio concentration in terms of the number of positions, sectors, or asset classes? How diversified is the portfolio?
• Leverage : How much leverage does the fund use? What is your approach to managing leverage risk?
• Team and Experience: Can you provide more information about the fund’s management team and their experience? What is your team’s background in the industry, and how does it complement the fund’s strategy?
• Operations and Infrastructure: How is the fund’s operational infrastructure set up? What service providers do you work with (e.g., administrators, auditors, prime brokers)?
• Capacity : What is the fund’s capacity, and how much assets under management (AUM) can your strategy effectively handle?
• Investor Base: What does your current investor base look like? How do you plan to grow and diversify the fund’s investor base?
• Alignment of Interests: How are the fund’s management and employees incentivized? Do the fund managers have a significant investment in the fund?
• Environmental, Social, and Governance (ESG) Factors: How do you incorporate ESG factors into your investment process, if at all?

Questions Pharma Startup Owners Ask

What is a pharma pitch deck.

A Pharma Pitch Deck is a presentation that startups in the biotech and healthcare industries create to introduce their company, technology, and drug development programs to potential investors. It includes information about the company, the market size, data addressing clinical trials, and the company’s intellectual property.

What is the importance of data in Biotech and Healthcare pitch decks?

A: Data is crucial in Biotech and Healthcare pitch decks because investors have a deep interest in the clinical and financial data that supports the company’s drug development, technology, or delivery platforms. Data points help to give confidence that the company’s ideas are backed by science.

What is a healthcare pitch deck, and how is it different from Pharma pitch deck?

A healthcare pitch deck is used to show how a company’s software or platform can be used to deliver improved patient care, help health insurers, etc. The difference lies in the breadth of the industries being served and the type of delivery. Healthcare pitch decks will avoid getting technical and instead focus on usage and market. Pharma pitch decks need to show technical knowledge, understanding of the clinical trial process, and any unique innovations affecting the outcome of the market.

What is intellectual property (IP)?

Intellectual property (IP) is a legal concept that protects the intangible assets of a company like the exclusive rights to a drug, patent-pending technology platform, or the trademark of a product. It enables the company to operate with the confidence that its innovative concepts, intellectual property, or trade secrets being kept confidentially and are protected from any replication from competitors.

How do I fundraise?

Fundraising requires a clear strategy. First, identify the milestone you plan to achieve, review your platform’s traction, and define the need for investing. Next, create a pitch deck for investors, and finally, identify potential investors and leverage your existing network to make introductions. Always show VCs what is impressive about your work, and the trick to fundraising is to make them excited about the possibilities. Even a small fundraise, you would never want to show an investor that you haven’t thought through the use of proceeds. Never forget that every startup is different, but highlighting the potential is a way of winning investors.

Successful biotech startups are those that identify a rare disease with an unmet medical need and enable its progression via a focus on personalized patient care. They will have a platform to convert data into meaningful insights, enabling better clinical trial outcomes.

When preparing for investor questions, be transparent and honest in your responses. Demonstrating a thorough understanding of your fund’s strategy, risk management, and operations will help build credibility and trust with potential investors.

And there you have it, the secret sauce to brewing a persuasive pharmaceutical pitch deck! Remember, a pitch deck is like a capsule — it might look small, but it needs to be potent, delivering the right amount of information at the right time. 

Create a story that not only informs but also connects emotionally. Present the data, but remember, nobody ever fell in love with a pie chart! Use visuals effectively, they’re your best friends in turning complex concepts into easily digestible bits. 

Finally, practice until your pitch flows as smoothly as a well-oiled machine. Because in the end, your goal is not just to inform, but to inspire action. And when that happens, it will be ‘mission accomplished’!

So, put on your lab coat, channel your inner scientist, and get ready to create a pitch deck that’s as revolutionary as the cure you’re pitching.

You got this!

But if you don’t got it :

Let me develop an investor ready deck by using my hands-off approach , which includes: market research, copy, design, financials, narrative and strategy.

More Resources

Check my cornerstone guide on pitch decks that helped my clients win more than 10,000,000$ in funding:

Startup Pitch Deck Guide: How To Create A Pitch Deck For Investors (Template Incl)

My proven step-by-step guide has helped my clients secure over $10 million in funding. Follow it to create a pitch deck that impresses investors. The guide covers:

• Building effective slides, such as the elevator pitch slide and financials slide
• Examples of successful startup pitch decks
• Understanding what investors are looking for
• Knowing what a pitch deck should and shouldn’t include
• Tips and tricks for creating a compelling presentation

Additionally, explore these resources for more information on pitch decks:

Also don’t miss out on my massive presentation specialist guide , last minute presentations and best business projector buyers guide.

Leave a Comment Cancel reply

Save my name, email, and website in this browser for the next time I comment.

Viktori . Pitching your way to your next funding. Or client.

Clutch Certified

Top Rated On Upwork

Viktori.co is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.

Pitch Deck Resources

• Pitch Deck Guides
• Pitch Deck Outlines
• Pitch Examples

Presentation Resources

• Presentation Guides
• Get A Pitch Deck

Office: 633 North Wells Street Chicago, IL, United States 60654 HQ : Boulevard P.O. 10000 Skopje, North Macedonia

Table of Contents

Newly Launched - World's Most Advanced AI Powered Platform to Generate Stunning Presentations that are Editable in PowerPoint

Powerpoint Templates

Icon Bundle

Kpi Dashboard

Professional

Business Plans

Swot Analysis

Gantt Chart

Business Proposal

Marketing Plan

Project Management

Business Case

Business Model

Cyber Security

Business PPT

Digital Marketing

Digital Transformation

Human Resources

Product Management

Artificial Intelligence

Company Profile

Acknowledgement PPT

PPT Presentation

Reports Brochures

One Page Pitch

Interview PPT

All Categories

Pharma company management powerpoint presentation slides

Introduce the measures for a safe and secure public health system by employing our Pharma Company Management PowerPoint Presentation Slides. Mention the key market trends related to robotics, ingestible sensors, nutrition technology, safety-focused wearables, mobile apps, and skintimate technology using these medical industry PPT templates. Take advantage of this content-ready health sector PPT slideshow to showcase global medical statistics in a well-organized format. To illustrate the building block of an optimized public health system, you can select these professionally designed nursing management PPT layouts. Pick this pharmaceutical management PPT presentation to efficiently display the flow of essential medical services. Our healthcare development PPT themes are well-formulated to exhibit the hospital and corporate tie-ups through various included charts, graphs, and tables. Impress the audience by highlighting the operating model of the biotech sector through these hospital management PowerPoint slides. Clearly define the healthcare finance policy with the medical sector administration PowerPoint presentation. Download this health industry PowerPoint deck to prepare an attractive yet informative presentation for your audiences.

• Add a user to your subscription for free

You must be logged in to download this presentation.

Do you want to remove this product from your favourites?

PowerPoint presentation slides

Presenting our Pharma Company Management PowerPoint Presentation Slides. This is a 100% editable and adaptable PPT slide. You can save it in different formats like PDF, JPG, and PNG. It can be edited with different colors, font, font sizes, and font types of the template as per your requirements. This template supports the standard (4:3) and widescreen (16:9) format. It is also compatible with Google Slides.

People who downloaded this PowerPoint presentation also viewed the following :

• Business Slides , Flat Designs , Concepts and Shapes , Complete Decks , All Decks , Business Plan Development , General
• Pharma Company Management ,
• Marketing ,

Content of this Powerpoint Presentation

Corporates who are in the pharma business line work in a highly restricted environment, requiring strict follow-ups to regulatory compliances. These regulations are related to medicine development, manufacturing, distribution, and marketing. Moreover, any new development essentially requires approvals, maintaining quality standards, monitoring, and reporting adverse events. Therefore pharmaceutical firm management is necessary to supply high-quality products to customers on time. This involves a meticulous set of processes between suppliers, manufacturers, retailers, and customers that includes supplying materials, information, and cash flow.

Moreover, these companies need to train people to manage pharmaceutical industrial units and their related sectors. This practice will help employees in planning and operating management techniques, identifying and solving management problems, and acquiring consultancy skills. This PPT Presentation on pharmaceutical management covers all aspects from training employees to helping in their crucial decision-making that'll ultimately reflect on the company image. Let’s explore the top slides of this PPT Presentation.

Template 1: Key Trends in Healthcare Industry

Healthcare practitioners must be adaptive, quick-thinkers, and flexible to satisfy the demands of their patients properly. This PPT Slide will help you sort out the seven key trends in the healthcare industry easily. The trends that are mentioned in the presentation template are Robotic companions, Ingestible health sensors, Fashionably healthy technology, Smart Nutrition Technology, Safety Focused Wearables, Mobile health for worried parents, and Skintimate technology. These trends are essential to understand the market and demand.

Template 2: Healthcare Industry Key Stats

Discuss facts and figures related to the healthcare industry in your region with this PPT Slide. Reveal the average expenditure on useful activities and money wasted on missed opportunities and inefficient services related to pharmaceutical business. Specify the hours required to meet patient care and the overall cost of health and social programs. Draw the comparison in terms of cross-checks numbers using this PPT Slide. The healthcare sector is expanding globally, creating more employment and generating more income in the process. Our PPT Design will help your audience enhance their knowledge about the healthcare industry's statistics.

Explain how R and D process works in the pharmaceutical industry with this content-rich presentation template  

Template 3: Medical Spending Global Statics

This PowerPoint Slide statistically displays the worldwide amount spent on medical healthcare. Use the first chart to display the highest to lowest percentage of the amount spent on medical care by the countries as shown. The second chart can be used to showcase the percentage of the type of product which is original brand, non-original band, unbranded, and OTC. The third and the last chart provide information about the disease-based expenses, which includes diabetes, infectious, autoimmune, respiratory, non-communicable, cardiovascular, and pain. With the help of our PPT Design, you can gain more knowledge about global statistics in healthcare.

Template 4: Global Healthcare Economy

The healthcare industry plays an important role in facilitating healthcare value, putting the needs of the patient first, and upgrading healthcare outcomes worldwide. In this PPT Layout, we can observe the different types of industries and the money invested in them with this Excel-lined pie chart template. Beauty & Anti-aging, fitness & mind-body, medicine & public health, spa industry, complementary & Alternative Medicine, and other healthcare industries can be compared in terms of their economy.

Template 5: Key Demand and Supply Drivers

Demand that remains constant regardless of price fluctuations characterizes the healthcare industry. Listed in this PPT Layout are the several critical demands including healthcare demographics, family and carer demographics, consumer health status and morbidity, health literacy levels, social determinants of health, consumer expectations and preferences, and health services affordability. Supplies that can cure those demands must be mentioned alongside as shown, such as health system funding and management, primary care capabilities, emergency care capability, health technology and infrastructure, rehabilitation and extended care capabilities. This presentation design can be crucial in understanding healthcare demands and supply to fulfill the demands of the patients.

Template 6: Public Health System

All governmental, commercial, and non-profit organizations that support the provision of necessary public health services within an authority come under the public health system. Our PowerPoint Design will give you a quick overview of the public healthcare system and help you identify which services are crucial for your business. This PPT Design in particular acknowledges three prominent public health systems that include: stakeholders, building blocks of optimized public health systems, and essential public health services.

Template 7: Stakeholders in Public Health System

Stakeholders play a vital role in the healthcare system as they encourage the pursuit of health-associated goods, services, research, and programs and handle the expenses of healthcare services. This PPT Template will help you learn about the stakeholders in the public health system. Highlight the importance of stakeholders in the development, execution, assessment, and financing of different healthcare initiatives. Discuss their significant impression on the outcome of any vital program using this presentation layout. These stakeholders will include hospitals, non-profit organizations, home health, employees, transit, mental health, law enforcement, and many more.

Check out this blog to learn about Achieving Sustainability In An Evolving Pharma Company Case Competition

Template 8: Building Block of Optimized Public Health System

Highlight the four critical factors required for the building blocks of an optimized Public Healthcare System, namely: Leadership and management skills, Technical Content, Operation System, and Finance System. Discuss their role and importance in improving the efficiency of public healthcare using creative pointer format as shown in this PPT Layout.

Template 9: Essential Public Health Services

Elaborate on the three essential elements under which the ten public health services fall into using this PPT Design. These are mentioned as assessment, policy development, and assurance. This PowerPoint presentation will help you understand that when it comes to working within communities, ten services such as monitoring healthcare, diagnosis, information, mobilizing community partnerships, developing policies, enforcing laws, etc will further contribute to defining the function and goal of public health.

Template 10: Pharma Company Operating Model

With this PPT Model, explain the critical factors of a pharmaceutical company's operations, culture, and surrounding environment. Specify the three crucial Value Proposition Articulation teams of the operating model with this PPT Design. These will be evidence generation and management. Connected delivery, and custom management. Using this PPT Guide, discuss the best ways to coordinate these aspects to create a fruitful and efficient pharma company.

Pharma companies are not easy to manage and handle as they work under so many regulations. The risk in this line of business is much bigger than a layman thinks because one wrong drug will cost you so many lives. However, managing the company is easy if you follow the footsteps of experts. For instance, with our expert-designed PPT Template you can simplify complex management tasks and get the work done efficiently.

PS: You can also explore these amazing templates on drug indication expansion in a pharma company case here.

Pharma company management powerpoint presentation slides with all 65 slides:

Use our Pharma Company Management Powerpoint Presentation Slides to effectively help you save your valuable time. They are readymade to fit into any presentation structure.

Ratings and Reviews

by Robert Young

December 23, 2021

by Smith Gomez

by Connor Lopez

by Delmer Black

by Drew Alvarado

February 11, 2021

by Edwardo Wheeler

by Darwin Mendez

by Cole Butler

What can we help you find?

Events & presentations.

Merck & Co., Inc. at the Goldman Sachs 45th Annual Global Healthcare Conference

• Apple Calendar
• Google Calendar
• Outlook Calendar

Icons / 16 / Microphone Created with Sketch. Webcast

June 11, 2024

July 30, 2024

Merck & Co., Inc. Q2 2024 Earnings Call

October 31, 2024

Merck & Co., Inc. Q3 2024 Earnings Call

February 04, 2025

Merck & Co., Inc. Q4 2024 Earnings Call

April 24, 2025

Merck & Co., Inc. Q1 2025 Earnings Call

July 29, 2025

Merck & Co., Inc. Q2 2025 Earnings Call

October 30, 2025

Merck & Co., Inc. Q3 2025 Earnings Call

June 03, 2024

Merck & Co., Inc. Investor Event at ASCO 2024

May 28, 2024

Merck & Co., Inc. 2024 Annual Meeting of Shareholders

May 15, 2024

Merck & Co., Inc. at the Bank of America Securities 2024 Healthcare Conference

April 25, 2024

Merck & Co., Inc. Q1 2024 Earnings Call

March 12, 2024

Merck & Co., Inc. at the Barclays 26th Annual Global Healthcare Conference

March 11, 2024

Merck & Co., Inc. at the Leerink Partners 2024 Global Biopharma Conference

March 05, 2024

Merck & Co., Inc. at the TD Cowen 44th Annual Healthcare Conference

February 01, 2024

Merck & Co., Inc. Q4 2023 Earnings Call

January 08, 2024

Merck & Co., Inc. at the 42nd Annual J.P. Morgan Healthcare Conference

January 04, 2024

Merck & Co., Inc. at the Goldman Sachs Healthcare C-Suite Unscripted Conference

Sign up for email alerts

Receive company news, updates and other information

Unsubscribe from email alerts

Contact investor relations

Forward-looking statement of merck & co., inc., rahway, n.j., usa.

This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). No Duty to Update The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

You are leaving Merck.com

Welcome to merck.com.

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.

• Our Company
• Sustainability Approach
• Access to Medicines
• Sustainability Disclosures
• Transparency Disclosures
• Corporate Giving
• Governance Strategy
• Governance Structure
• Charters and Reports
• Areas of Focus
• Research and Development
• Our Products
• Manufacturing
• Clinical Trials
• Our Stories
• Press Releases
• Media Resources
• Financial Results

Investor Events

• Investor Contact

Investor Events and Presentations | Takeda Pharmaceuticals

Financial Highlights

• Quarterly Results
• Stock Information & Shareholder Returns
• Securities Report & Form 20-F

Earnings Announcement Meetings / IR Events / Broker Conferences

• Upcoming Events
• FY2024 Past Events

Quarterly Results - Quarter 1 FY2024

(July 31, 2024)

Quarterly Results - Quarter 2 FY2024

(October 31, 2024)

TAK-861 Investor Call on Phase 2b Narcolepsy Type 1 Data

(7:30pm- 8:30pm CDT, 8:30pm - 9:30pm EDT on June 3, 2024)

Webcast Go to https://www.irwebcasting.com/20240604/4/index.html

• Presentation

Quarterly Results - Quarter 4 FY2023

(May 9, 2024)

Event Archive

FY2023 (April 2023-March 2024)

Cowen 44 th Health Care Conference

(9:50am – 10:20am EST on March 6, 2024)

• This event was closed.

Quarterly Results - Quarter 3 FY2023

(February 1, 2024)

42nd Annual J.P. Morgan Healthcare Conference

(5:15pm – 5:55pm PST on January 8, 2024)

Plasma-Derived Therapies Investor Event

(6:00 – 7:00pm EST on December 5, 2023)

• Webcast Go to https://www.irwebcasting.com/20231206/3/index.html

Jefferies London Healthcare Conference

(4:00 – 4:25am EST on November 14, 2023)

(9:00 – 9:25am GMT on November 14, 2023)

Quarterly Results - Quarter 2 FY2023

(October 26, 2023)

Morgan Stanley Healthcare Conference

(3:35 – 4:05pm EDT on September 11, 2023)

Quarterly Results - Quarter 1 FY2023

(July 27, 2023)

Quarterly Results - Quarter 4 FY2022

(May 11, 2023)

FY2022 (April 2022-March 2023)

TAK-279 (TYK2 inhibitor) Investor Call on Phase 2b Psoriasis Data

(March 18, 2023)

Webcast Go to https://www.irwebcasting.com/20230319/2/index.html

QDENGA Investor call

(March 15, 2023)

Webcast Go to https://www.irwebcasting.com/20230316/2/index.html

Cowen 43rd Health Care Conference

(March 6, 2023)

Quarterly Results - Quarter 3 FY2022

(February 2, 2023)

41st Annual J.P. Morgan Healthcare Conference

(January 9, 2023)

Conference call regarding acquisition of NDI-034858 From Nimbus Therapeutics

(December 13, 2022)

Webcast Go to https://www.irwebcasting.com/20221214/3/index.html

(November 15, 2022)

Quarterly Results - Quarter 2 FY2022

(October 27, 2022)

Seminar: Investors and Analysts on Lysosomal Storage Diseases (LSD)

(October 4, 2022)

Webcast Go to https://www.irwebcasting.com/20221004/2/index.html

(September 12, 2022)

Quarterly Results - Quarter 1 FY2022

(July 28, 2022)

Jefferies Healthcare Conference

(June 9, 2022)

Quarterly Results - Quarter 4 FY2021

(May 11, 2022)

FY2021 (April 2021-March 2022)

Cowen 42 nd  Health Care Conference

(2:50pm – 3:20pm EST on March 8, 2022)

Seminar: Investors and Analysts on Short Bowel Syndrome (SBS) and Complex Crohn’s Perianal Fistulas (CPF)

(1:00pm JST on February 24, 2022)

Webcast Go to https://www.irwebcasting.com/20220224/2/index.html

Quarterly Results - Quarter 3 FY2021

(Held on February 3, 2022)

40 th  Annual J.P. Morgan Healthcare Conference

(4:30pm – 5:10pm EST on January 10, 2022)

Takeda Management Call

(6:00pm – 7:00pm EST on January 10, 2022)

(5:30pm – 7:30pm EST on November 17, 2021)

Quarterly Results - Quarter 2 FY2021

(Held on October 28, 2021)

Quarterly Results - Quarter 1 FY2021

(Held on July 30, 2021)

Finance Investor Day

(7:00pm – 9:00pm EDT on July 12, 2021)

Oncology Strategic Update Call

(6:30pm – 7:45pm EDT on June 8, 2021)

2021 Biopharma CEO Investor Forum

(8:00am – 8:50am EDT on June 7, 2021)

Wave 1 Pipeline Market Opportunity Call Part 2

(8:00am – 10:30am EDT on April 6, 2021)

R&D Pipeline Factsheet

Quarterly Results - Quarter 4 FY2020

(Held on May 11, 2021)

FY2020 (April 2020-March 2021)

Growth and Emerging Markets Strategic Update Call

(6:30am-8:15am EST on March 11, 2021)

Seminar: Investors and Analysts on Takeda’s Japan Oncology Business and its oncology products and disease in Japan

(1:00pm-2:45pm JST on February 25, 2021)

Quarterly Results - Quarter 3 FY2020

(Held on February 4, 2021)

World Conference on Lung Cancer (WCLC) Investor Event

(5:00pm-6:00pm EST on January 29, 2021)

39 th  Annual J.P. Morgan Healthcare Conference

(5:20pm-6:00pm EST on January 11, 2021)

Wave 1 Pipeline Market Opportunity Call

(5:00pm-7:15pm EST on December 8, 2020)

Quarterly Results - Quarter 2 FY2020

(Held on October 29, 2020)

Seminar: Investors and Analysts on Inflammatory Bowel Disease

(1:00pm JST on September 2, 2020)

Quarterly Results - Quarter 1 FY2020

(Held on July 31, 2020)

Seminar: Investors and Analysts on Hereditary Angioedema (HAE)

(1:00pm JST on June 30, 2020)

Oncology Focused Investor Call

(8:00am EDT / 9:00pm JST on June 8, 2020)

Quarterly Results - Quarter 4 FY2019

(Held on May 13, 2020)

FY2019 (April 2019-March 2020)

Quarterly Results - Quarter 3 FY2019

(Held on February 4, 2020)

38 th  Annual J.P. Morgan Healthcare Conference

(4:00pm-4:55pm PST on January 14, 2020)

R&D Day and Plasma-Derived Therapies Day in Tokyo

(11:00am-5:00pm JST on November 21, 2019)

Plasma-Derived Therapies

Plasma-Derived Therapies Overview: Julie Kim, President, Plasma-Derived Therapies Business Unit

Plasma-Derived Therapies R&D: Christopher Morabito, Head, R&D, Plasma-Derived Therapies

Click to Download

R&D Day

Click to Download the slides

Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader: Christophe Weber, President & CEO

Translating Science into Highly Innovative, Life-changing Medicines: Andy Plump, President, R&D

Oncology and Cell Therapies with Spotlight on CAR-NK: Chris Arendt, Head, Oncology Drug Discovery Unit

Spotlight on Oncology Opportunities TAK-788: Rachael Brake, Global Program Leader, Oncology

Spotlight on Oncology Opportunities Pevonedistat: Phil Rowlands, Head, Oncology Therapeutic Area Unit

Rare Diseases & Gene Therapy: Dan Curran, Head, Rare Disease Therapeutic Area Unit

Spotlight on Orexin2R agonists: Deborah Hartman, Global Program Leader, Neuroscience

Therapeutic Area Focus in GI with Spotlight on Celiac Disease: Asit Parikh, Head, GI Therapeutic Area Unit

Takeda R&D Pipeline Narrative

Plasma-Derived Therapies Day in Covington, Georgia

(11:15am-3:45pm EST on November 15, 2019)

Covington Site Introduction: Carlos Soto, Covington Site Head

R&D Day in New York

(12:30pm-4:00pm EST on November 14, 2019)

Welcome and Opening Remarks: Sheelagh Cawley-Knopf, Head, R&D Global Portfolio Strategy

Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader : Christophe Weber, President & CEO

Translating Science into Highly Innovative, Life-changing Medicines : Andy Plump, President, R&D

Oncology and Cell Therapies with Spotlight on CAR-NK : Chris Arendt, Head, Oncology Drug Discovery Unit

Spotlight on Oncology Opportunities TAK-788 : Rachael Brake, Global Program Leader, Oncology

Spotlight on Oncology Opportunities Pevonedistat : Phil Rowlands, Head, Oncology Therapeutic Area Unit

Rare Diseases & Gene Therapy : Dan Curran, Head, Rare Disease Therapeutic Area Unit

Spotlight on Orexin2R agonists : Deborah Hartman, Global Program Leader, Neuroscience

Therapeutic Area Focus in GI with Spotlight on Celiac Disease : Asit Parikh, Head, GI Therapeutic Area Unit

Quarterly Results - Quarter 2 FY2019

(Held on October 31, 2019)

IR meeting with analysts and investors with Julie Kim, President of Takeda's Plasma-Derived Therapies Business Unit

(Held on October 10, 2019)

(Held on September 10, 2019 ET)

Quarterly Results - Quarter 1 FY2019

(Held on July 31, 2019)

IR Seminar “Plasma-Derived Therapies Business”

(Held on July 12, 2019)

Quarterly Results - Quarter 4 FY2018

(Held on May 14, 2019)

FY2018 (April 2018-March 2019)

Quarterly Results - Quarter 3 FY2018

(Held on February 1, 2019)

37 th  Annual J.P. Morgan Healthcare Conference

(Held on January 8, 2019 PST)

Meeting regarding Acquisition of Shire plc by Takeda

(Held on January 7, 2019)

Presentation : A Global, Values-based, R&D-driven Biopharmaceutical Leader

More details on Takeda's offer to acquire Shire Plc.

Quarterly Results - Quarter 2 FY2018

(Held on October 31, 2018)

Takeda’s R&D Investor Day (Boston)

(October 11, 2018)

Presentation : Delivering on our R&D vision

Andy Plump, Chief Medical and Scientific Officer

Gastroenterology

Neuroscience

Takeda’s R&D Investor Day (Tokyo)

(September 27, 2018)

Shonan iPark

Quarterly Results - Quarter 1 FY2018

(Held on July 31, 2018)

Quarterly Results - Quarter 4 FY2017

(Held on May 14, 2018)

Conference Call Regarding Proposed Acquisition of Shire plc by Takeda

(Held on May 8/9, 2018)

• Presentation : Takeda to Acquire Shire-Accelerating Takeda’s Transformation to Deliver More for Patients

FY2017 (April 2017-March 2018)

Quarterly Results - Quarter 3 FY2017

(Held on February 1, 2018)

36 th  Annual J.P. Morgan Healthcare Conference

(Held on January 8, 2018 PST)

Jefferies 2017 Global Healthcare Conference

(Presented November 16, 2017, 10:00 GMT)

Quarterly Results - Quarter 2 FY2017

(Held on November 1, 2017)

Quarterly Results - Quarter 1 FY2017

(Held on July 28, 2017)

UBS Global Healthcare Conference

(Released on May 23, 2017, 9:30 EDT)

Quarterly Results - Quarter 4 FY2016

(Held on May 10, 2017)

FY2016 (April 2016-March 2017)

Quarterly Results - Quarter 3 FY2016

(Held on February 1, 2017)

Conference Call on the Acquisition of ARIAD Pharmaceuticals

(Released on January 10, 2017)

35 th Annual J.P. Morgan Healthcare Conference

(Held on January 9, 2017)

Quarterly Results - Quarter 2 FY2016

(Held on October 28, 2016)

Quarterly Results - Quarter 1 FY2016

(Held on July 29, 2016)

Takeda IR Day

(Held on June 9, 2016)

Takeda Oncology: Christophe Bianchi, President, Global Oncology Business Unit

Focused World Class R&D New approaches to innovation: Andrew Plump, Chief Medical & Scientific Officer

Quarterly Results - Quarter 4 FY2015

(Held on May 10, 2016)

FY2015 (April 2015-March 2016)

Quarterly Results - Quarter 3 FY2015

(Held on February 3, 2016)

34th Annual J.P. Morgan Healthcare Conference

(Held on January 12, 2016)

Quarterly Results - Quarter 2 FY2015

(Held on October 30, 2015)

Quarterly Results - Quarter 1 FY2015

(Held on July 30, 2015)

Quarterly Results - Quarter 4 FY2014

(Held on May 15, 2015)

FY2014 (April 2014-March 2015)

Takeda IR Event: A Global Leader in Gastroenterology

(Held on March 9, 2015)

Quarterly Results - Quarter 3 FY2014

(Held on February 5, 2015)

33 rd  Annual J.P. Morgan Healthcare Conference

(Held on January 13, 2015)

Quarterly Results - Quarter 2 FY2014

(Held on October 30, 2014)

Quarterly Results - Quarter 1 FY2014

(Held on August 1, 2014)

Quarterly Results - Quarter 4 FY2013

(Held on May 8, 2014)

FY2013 (April 2013-March 2014)

Quarterly Results - Quarter 3 FY2013

(Held on February 5, 2014)

32 nd  Annual J.P. Morgan Healthcare Conference

(Held on January 13, 2014)

Quarterly Results - Quarter 2 FY2013

(Held on October 31, 2013)

Quarterly Results - Quarter 1 FY2013

(Held on July 31, 2013)

Annual Shareholders Meetings

148th ordinary general meeting of shareholders (june 26, 2024).

Notice of Convocation of the 148th Ordinary General Meeting of Shareholders

Other items which are provided electronically

Message from Christophe Weber, President & CEO

Takeda’s executive compensation overview

FY2023 Q4 Financial Results

Past Shareholder Events & Reports

147th Ordinary General Meeting of Shareholders(June 28, 2023)

Notice of Convocation of the 147th Ordinary General Meeting of Shareholders

FY2022 Q4 Financial Results

Partial Correction to the Notice of Convocation of 147th Ordinary General Meeting of Shareholders

Notice of Resolutions

Results of the Exercise of Voting Rights

147th Interim Report

• Business report (interim period)

146th Ordinary General Meeting of Shareholders(June 29, 2022)

Notice of convocation

Items disclosed via the Internet Concerning the Notice of Convocation of the Ordinary General Meeting of Shareholders

Takeda's executive compensation overview

146th Interim Report

145th Ordinary General Meeting of Shareholders (June 29, 2021)

Notice of Convocation

Items Disclosed via the Internet Concerning the Notice of Convocation of the Ordinary General Meeting of Shareholders

Partial Correction to the Notice of Convocation of the 145th Ordinary General Meeting of Shareholders

145th Interim Report

144th Ordinary General Meeting of Shareholders (June 24, 2020)

Partial Correction to the Items Disclosed via the Internet Concerning the Notice of Convocation of the 144th Ordinary General Meeting of Shareholders

144th Ordinary General Meeting of Shareholders Christophe Weber

144th Interim Report

143rd Ordinary General Meeting of Shareholders (June 27, 2019)

Partial Correction to the Notice of Convocation of the 143rd Ordinary General Meeting of Shareholders

Supplemental Material for the Proposals at the 143rd Ordinary General Meeting of Shareholders

Summary of Takeda’s Modifications to the Executive Compensation Program and Future Considerations

Takeda’s Recommendation to vote for Takeda’s Proposals at the 143rd Ordinary General Meeting of Shareholders

A Statement of Confidence in the Leadership of Mr. Christophe Weber and Comments on the Proposals at the 143rd Ordinary General Meeting of Shareholders from Masahiro Sakane, the Chair of the Board of Directors Meeting of Takeda

Consolidated Financial Results for FY2018 and Guidance for FY2019

143rd Interim Report

Extraordinary General Meeting of Shareholders (December 5, 2018)

Message from Christophe Weber, President & CEO, regarding the acquisition of Shire plc

Partial Correction to the Reference Document attached to the Notice of Convocation of the Extraordinary General Meeting of Shareholders

Results of the Exercise of voting Rights

Learn more about the Shire offer

Retail Investor Events

Online information session for retail investors: "committed to growth & shareholder returns" (in japanese only).

7:45 pm - 8:30 pm JST on February 22, 2024

• Webcast Go to https://api01-platform.stream.co.jp/apiservice/plt3/NTk0NA%3d%3d%23NTI3Mg%3d%3d%23280%23168%23b%233FE2A0D9E400%23MDoyOjc6YTpmOzEwOzEwOzEw%23

Information session for retail investors: "Better health for people, Brighter future for the world"

February 22, 2023

Sign up for our investors newsletter

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

The company’s most recent and important financial information

Read our latest news

• All Resource

PPT Templates

Single slides.

• Pitch Deck 209 templates
• Animation 326 templates
• Vertical Report 316 templates
• Business 803 templates
• Finance 56 templates
• Construction 45 templates
• IT/Commerce 171 templates
• Medical 64 templates
• Education 45 templates
• Lifestyle 394 templates
• Pitch Decks 138 templates
• Business 541 templates
• Finance 20 templates
• Construction 75 templates
• IT/Commerce 73 templates
• Medical 27 templates
• Lifestyle 578 templates
• Pitch Decks 140 templates
• Business 469 templates
• Finance 19 templates
• Construction 64 templates
• IT/Commerce 72 templates
• Medical 29 templates
• Education 39 templates
• Lifestyle 490 templates
• Cover 266 templates
• Agenda 97 templates
• Overview 216 templates
• CEO 28 templates
• Our Team 142 templates
• Organization 48 templates
• History 38 templates
• Vision, Mission 109 templates
• Problem, Solution 193 templates
• Opportunity 154 templates
• Business Model 158 templates
• Product, Services 299 templates
• Technology 65 templates
• Market 155 templates
• Prices 56 templates
• Customers 55 templates
• Competitor 113 templates
• Business Process 151 templates
• Analysis 222 templates
• Strategy 120 templates
• Marketing, Sales 61 templates
• Profit, Loss 69 templates
• Financials 247 templates
• Timeline 122 templates
• Proposal 40 templates
• Contact Us 272 templates
• Break Slides 16 templates
• List 361 templates
• Process 351 templates
• Cycle 177 templates
• Hierarchy 98 templates
• Relationship 152 templates
• Matrix 86 templates
• Pyramid 67 templates
• Tables 145 templates
• Map 96 templates
• Puzzles 163 templates
• Graph 217 templates
• Infographics 436 templates
• SWOT 111 templates
• Icon 418 templates
• Theme Slides 138 templates
• Mockup 42 templates
• Column 315 templates
• Line 199 templates
• Pie 139 templates
• Bar 179 templates
• Area 130 templates
• X Y,Scatter 16 templates
• Stock 59 templates
• Surface 3 templates
• Doughnut 256 templates
• Bubble 65 templates
• Radar 83 templates
• Free PPT Templates 2,101 templates
• Free Keynote 2,017 templates
• Free Google Slides 2,098 templates
• Free Theme Slides 35 templates
• Free Diagram 126 templates
• Free Chart 49 templates
• New Updates

Result for ' pharmaceutical '

37 Templates are available.

• Sort by Accuracy
• Sort by Newest

pharmaceutical Industry Interactive PPT

Quick and easy to customize Built-in custom color palette Data charts (editable via Excel) No animation template Modern layouts based on master slides

pharmaceutical Company ppt presentation slides

Easy customization Fully editable content (graphics and text) via PowerPoint - No Photoshop needed! Professional and unique slides Professionally designed infographic templates Shapes: fully editable vector graphics

Health Medical Slide Presentation

Quick and easy to customize Easy to change colors All images included Format: PowerPoint (.pptx) - designed with Microsoft PowerPoint 2016

Happy Thanksgiving Slide Presentation

Quick and easy to customize Data charts (editable via Excel) 16:9 aspect ratio Drag & drop image placeholders

Delicious food project PowerPoint Templates

Easy to edit and customize Fully editable content (graphics and text) via PowerPoint - No Photoshop needed! 16:9 aspect ratio Professional business presentation Drag & drop image placeholders

3D Area Chart (Pharmacy)

Easily editable data driven charts (pie, bar, line) Aspect ratio - 4:3 (normal), 16:9 (widescreen) Easy to change colors

Bubble Scatter (Pharmacy)

2 aspect ratios (4:3 & 16:9) Dark & light backgrounds Easy to change colors

Clustered Bar (Pharmacy)

Clustered Column (Pharmacy)

Easily editable data driven charts (pie, bar, line) 2 aspect ratios (4:3 & 16:9) Dark and light versions of each Easy color change

Doughnut Chart (Pharmacy)

Data charts editable via Excel Aspect ratio - 4:3 (normal), 16:9 (widescreen) Easy to change colors

Comparison Line Chart (Pharmacy)

2 aspect ratios (4:3 & 16:9) 100% editable via Excel Dark & light backgrounds Easy color change

Radar with Markers (Pharmacy)

2 aspect ratios (4:3 & 16:9) Data charts editable via Excel Easy color change

Scatter with Smooth Lines and Markers (Pharmacy)

3D Pie Chart (Pharmacy)

100% editable via Excel Dark and light versions of each Easy color change

100% Stacked Column (Pharmacy)

100% editable via Excel 16:9, 4:3 aspect ratios Dark & light backgrounds Easy color change

Open-High-Low-Close (Pharmacy)

Data charts editable via Excel Dark and light versions of each Easy color change

Pie with Clustered Column Chart (Pharmacy)

100% editable via Excel 16:9, 4:3 aspect ratios Easy to change colors

Medical Service Pitch Deck PowerPoint Templates

Modern, simple, and clean design Quick and easy to customize Highly editable presentation template. Easy to change colors Free images and artwork

Startup Pitch Deck Presentation Format

Easy customization Easy to edit and customize Data charts (editable via Excel) Vector icons 100% editable Smart and innovative presentation slides

Diabetes PowerPoint Presentation Examples

Quick and easy to customize Easy to change colors Data charts (editable via Excel) All images included Professional business presentation All elements are editable

Free Slides

Slide Members

[email protected]

All Rights Reserved 2024 © Copyright Slide Members

Information

• Privacy Policy
• Terms & Conditions

Recent Slides

• 26+ Latest weekly update Powerpoint Templates & Google slides
• 19+ Recently Powerpoint Templates & Google slides Update
• 9+ New Powerpoint Templates & Google Slides Update

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• EV Deep Dive
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Student Loans
• Personal Loans
• Car Insurance
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Tonix pharmaceuticals announces poster presentation at the annual european congress of rheumatology (eular) 2024.

Presentation to highlight statistically significant Phase 3 results of Tonmya™ (TNX-102 SL) for the management of fibromyalgia

New Drug Application (NDA) submission to the FDA on track for the second half of 2024

CHATHAM, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2024, being held June 12-15, 2024 at the Messe Wien Congress Center in Vienna, Austria. Details on the presentation can be found below.

A copy of the Company’s poster presentations will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the EULAR website here .

Poster Presentation Details

Tonix Pharmaceuticals Holding Corp. *

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace ® SymTouch ® (sumatriptan injection) 3 mg and Tosymra ® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

1 Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com .

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris Tonix Pharmaceuticals [email protected] (862) 904-8182

Peter Vozzo ICR Westwicke [email protected] (443) 213-0505

Media Contact

Katie Dodge LaVoieHealthScience [email protected] (978) 360-3151

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

26 templates

great barrier reef

17 templates

15 templates

football soccer

22 templates

18 templates

49 templates

Pharmacy Presentation templates

Medication helps us ease the symptoms of some diseases, and to get them you need to go to the pharmacy. our prescription to create great presentations about this topic is easy: download and edit these google slides and powerpoint templates.

It seems that you like this template!

Pharmacovigilance.

Download the Pharmacovigilance presentation for PowerPoint or Google Slides. Healthcare goes beyond curing patients and combating illnesses. Raising awareness about diseases, informing people about prevention methods, discussing some good practices, or even talking about a balanced diet—there are many topics related to medicine that you could be sharing with everyone....

Premium template

Unlock this template and gain unlimited access

Pharmaceutical Lab Business Plan

Pharmacology is one of the most important fields of the health industry (it already was when Dioscorides was alive!) Unlike our medieval predecessors, we rely on different labs to do some research and to patent and sell new remedies. Promote your Pharmaceutical Lab Business Plan with our template!

Pharmacy Slideshow

Send your audience a trustworthy message that lists the best aspects of your pharmacy or healthcare center. What you'll get with this template is a relatively simple slideshow with flat illustrations and a palette composed of pink and orange tones. There're also medical icons that strengthen the context!

Everyday Pills Calendar

When we take several medications it is easy to end up getting confused and wondering if we have taken one dose, two or none. With this pill calendar we bring you the solution. It is divided by months, so you can use it throughout the year. It has a colorful...

Pharmacy Minitheme

Going to the pharmacy has become a regular habit for a lot of people. No, not because they need medicines all the time, but because they sell masks! Anyways, we are glad that pharmacists work so hard, so we've decided to design this minitheme. It's a set of twenty slides...

Pharmacy Project Proposal

Do you know that Slidesgo is like a pharmacy on call? You can find the perfect template 24 hours a day! And speaking of pharmacies and templates... We've combined both, in case you're looking for a design with which to present a project proposal in relation to a pharmacy. We...

Pharmacy Case Report: Effect of Antidepressants

Download the Pharmacy Case Report: Effect of Antidepressants presentation for PowerPoint or Google Slides. A clinical case is more than just a set of symptoms and a diagnosis. It is a unique story of a patient, their experiences, and their journey towards healing. Each case is an opportunity for healthcare...

Pharmacy Infographics

Since healthcare is a serious matter, upping your game and making your message more visual helps your audience be more receptive to the topic. Use these infographics to talk about medicine or pharmacy. For example, you can use these designs to present a new medicament or provide some statistics on...

Pharmaceutic Industry Breakthroughs

Breakthroughs in the pharmaceutical industry are always a cause of joy, since they usually imply improvements in the quality of life of many people. Use this simple orange template to share your latest discoveries. It includes text boxes to explain the context and introduce the topic; charts to show objectives,...

Pharmacopeia

There are regular encyclopedias and then there are pharmacopeias, books that contain information about medicines. Such an useful item can be turned into a presentation if you use this template! Its simple design is, however, complemented by an assortment of illustrations of all kinds of pills, caplets, capsules and other...

Pharmacy Major for College: Pharmacology

Download the Pharmacy Major for College: Pharmacology presentation for PowerPoint or Google Slides. As university curricula increasingly incorporate digital tools and platforms, this template has been designed to integrate with presentation software, online learning management systems, or referencing software, enhancing the overall efficiency and effectiveness of student work. Edit this...

Pharmacology and Toxicology Thesis Defense

Download the Pharmacology and Toxicology Thesis Defense presentation for PowerPoint or Google Slides. Congratulations, you have finally finished your research and made it to the end of your thesis! But now comes the big moment: the thesis defense. You want to make sure you showcase your research in the best...

Polypharmacy Breakthrough

Polypharmacy consists of taking more than five medications daily in a very continuous manner and for more than six months. The presence of polypharmacy is usually found in older people, because, due to their age, they need or believe they need a massive consumption of drugs. However, this is a...

Pharmacy Case Report: Effect of Opioids

Download the Pharmacy Case Report: Effect of Opioids presentation for PowerPoint or Google Slides. A clinical case is more than just a set of symptoms and a diagnosis. It is a unique story of a patient, their experiences, and their journey towards healing. Each case is an opportunity for healthcare...

Substance Abuse Problems

Raising awareness of the problems derived from abuse of certain substances can be very informative for society. This new template has been created for the medical community, and can be used to explain a clinical case related to drugs, smoking or other things. Apart from dark gray backgrounds and rounded...

Cream & Pastel Palette Healthcare Center Characters

Let us introduce you to a new way of presenting healthcare centers. Did you think that we were going to use blue? Tut-tut! This time, the palette revolves around cream (the color of the backgrounds) and other pastel tones. As you explain in detail (or in brief) your healthcare services,...

Pharmacology - Bachelor of Science in Nursing

Introduce your Bachelor students to the world of pharmacology with this comprehensive Google Slides and PowerPoint template. It’s fully customizable and perfect for building a strong foundational knowledge. From outlining various medications and their administration routes to discussing potential side effects, the blue and gray slides decorated with medication illustrations...

Pharmacology - Doctor of Medicine (M.D.)

Download the "Pharmacology - Doctor of Medicine (M.D.)" presentation for PowerPoint or Google Slides. As university curricula increasingly incorporate digital tools and platforms, this template has been designed to integrate with presentation software, online learning management systems, or referencing software, enhancing the overall efficiency and effectiveness of student work. Edit...

• Page 1 of 3

Register for free and start editing online

UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024

• ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completed
• Results from the ADESOS study have been selected for an oral presentation at the late breaking research sessions at the RAVE Conference 2024
• Orismilast is a next generation, high potency PDE4 B/D selective inhibitor with reported positive results from a Phase 2b study in psoriasis and Phase 2 study in hidradenitis suppurativa (HS); orismilast is currently being evaluated in an ongoing IIT study in ulcerative colitis (UC)
• UNION is progressing orismilast to Phase 3 development in AD

Hellerup, Denmark, June 4, 2024 - UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announces successful completion of the ADESOS Phase 2b, randomized, dose-finding study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe AD.

Topline results from the ADESOS study have been selected for an oral presentation by the Signatory Investigator, Professor Jonathan Silverberg, MD, PhD, MPH at the late breaking research sessions at Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) Conference on June 8-10, 2024, in Chicago, United States. It will be the first presentation of data from the ADESOS study.

Presentation details

Presentation: Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a Phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS)

Presenter: Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Signatory Investigator for ADESOS

Date and time: Monday June 10, 2024, at 1:30 PM - 4:40 PM CDT.

Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences   and Signatory Investigator for ADESOS study said:  

"AD is one of the most common chronic inflammatory skin diseases worldwide. Innovation in recent years has brought good injectable treatments to patients, but a significant unmet medical need for a safe and effective oral treatment still exists. Orismilast offers the potential for a safe oral treatment with early itch reduction and holds a significant promise as a novel treatment option in AD."

Kim Kjøller, Co-Chief Executive Officer of UNION therapeutics adds:

"The results from the ADESOS study with orismilast in atopic dermatitis (AD) follows positive read outs in psoriasis and hidradenitis suppurativa (HS) confirming the potential of orismilast as a safe oral treatment across immunology. We are pleased that the Phase 2b results from the ADESOS study have been selected for an oral presentation at the RAVE Conference in Chicago and look forward to the results being shared and discussed with the leading experts in the field."

Orismilast is developed as a next-generation, high potency PDE4B/D selective inhibitor targeting first-in-class positions in AD and hidradenitis suppurativa (HS), and best in class in psoriasis. The efficacy and safety profile of orismilast have been evaluated in the previously reported IASOS Phase 2b study in psoriasis and OSIRIS Phase 2 study in HS. Data of these studies has been presented at leading scientific conferences and data is published in peer-reviewed journals, including the Journal of American Academy of Dermatology (JAAD) and the Journal of European Academy of Dermatology and Venerology (JEADV).

UNION has scheduled an End of Phase 2 meeting with the FDA to discuss advancing the orismilast development program into Phase 3 studies in AD.  

About the ADESOS Phase 2b study

The Phase 2b study was a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of orismilast in patients with moderate to severe AD. The study included 233 patients who were randomized to three active doses (20mg, 30mg, and 40 mg) of orismilast or placebo administered twice daily. The study was conducted in centers in Europe and in the US.

About orismilast

Orismilast is a next generation, high potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It acts early in the inflammation cascade, inducing a broad range of anti-inflammatory effects across multiple cytokines involved in many dermatological and immunological diseases.1)

UNION is developing orismilast as an oral treatment, based on the well-known safety profile of the PDE4 class, across immunology, initially targeting best-in-class or first-in-class positions in atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis and ulcerative colitis (UC).

The FDA has cleared UNION's Investigational New Drug (IND) application for orismilast and granted Fast Track designation for orismilast for the treatment of moderate to severe AD as well as for the treatment of moderate to severe HS.

About atopic dermatitis

AD is a chronic inflammatory skin disease affecting 2.1-4.9 % of the adult population worldwide and is the most common skin disease among children.2) There were approximately 20 million diagnosed moderate-to-severe adult patients with AD in 2023 in the Seven Major Markets (United States, France, Germany, Italy, Spain, UK, and Japan).3) Disease symptoms are characterized by recurrent eczematous skin lesions and intense itch. AD has a substantial psychosocial impact on patients and relatives.4) During disease flares, approximately 80% of patients may experience disturbed sleep, which may also disrupt the sleep of family members.5) The disease also appears to impact the mood and patients have an increased risk of anxiety and depression.6)

1)       Blauvelt A et al., Dermatology and Therapy 2023: Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review - PubMed (nih.gov) &

Silverberg J.I. et al., JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18818  &

Warren R.B. et al., JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18812

2)       Barbarot S et al,. Allergy 2018: https://pubmed.ncbi.nlm.nih.gov/29319189/ https://pubmed.ncbi.nlm.nih.gov/25925336/

3)       EvaluatePharma 2023

4)       Laughter MR et al., British Journal of Dermatology 2021: https://pubmed.ncbi.nlm.nih.gov/33006135/

5)       Eichenfield LF et al., Journal of the American Academy of Dermatology 2014: https://pubmed.ncbi.nlm.nih.gov/24290431/

6)       Drucker AM et al., The Journal of Investigative Dermatology 2017: https://pubmed.ncbi.nlm.nih.gov/27616422/

Morten Boesen, Chief Financial Officer, UNION therapeutics A/S

+45 2381 5487

[email protected]

Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S

+45 5385 3044

[email protected]

About UNION therapeutics

UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-successful-completion-of-the-adesos-phase-2b-study-and-presentation-of-%2Cc3994646

• Christers presentation from Redeye Growth Day 2024.

Presentation of the company and the development of linaprazan glurate from Redeye Growth Day 2024.

Here you can watch the full presentation (in Swedish) of CInclus Pharma and the development of linaprazan glurate, held by CEO Christer Ahlberg at   Redeye Growth Day 2024:

Cinclus Pharma: InFocus interview with CEO Christer Ahlberg at Redeye Growth Day 2024 – 30 May

• Share full article

Advertisement

Supported by

Lawyers to Plastics Makers: Prepare for ‘Astronomical’ PFAS Lawsuits

At an industry presentation about dangerous “forever chemicals,” lawyers predicted a wave of lawsuits that could dwarf asbestos litigation, audio from the event revealed.

By Hiroko Tabuchi

The defense lawyer minced no words as he addressed a room full of plastic-industry executives. Prepare for a wave of lawsuits​ with​ potentially “astronomical” costs​. Speaking at a conference earlier this year, the lawyer, Brian Gross, said the coming litigation could “dwarf anything related to asbestos,” one of the most sprawling corporate-liability battles in United States history.

Mr. Gross was referring to PFAS, the “forever chemicals” that have emerged as one of the major pollution issues of our time. Used for decades in countless everyday objects — cosmetics, takeout containers, frying pans — PFAS have been linked to serious health risks including cancer. Last month the federal government said several types of PFAS must be removed from the drinking water of hundreds of millions of Americans .

“Do what you can, while you can, before you get sued,” Mr. Gross said at the February session, according to a recording of the event made by a participant and examined by The New York Times. “Review any marketing materials or other communications that you’ve had with your customers, with your suppliers, see whether there’s anything in those documents that’s problematic to your defense,” he said. “Weed out people and find the right witness to represent your company.”

A spokesman for Mr. Gross’s employer, MG+M The Law Firm, which defends companies in high-stakes litigation, didn’t respond to questions about Mr. Gross’s remarks and said he was unavailable to discuss them.

A wide swath of the chemicals, plastics and related industries are gearing up to fight a surge in litigation related to PFAS, or per- and polyfluoroalkyl substances, a class of nearly 15,000 versatile synthetic chemicals linked to serious health problems.

PFAS chemicals have been detected almost everywhere scientists have looked: in drinking water, in rain falling over the Great Lakes , even in Antarctic snow . They are thought to be present in the blood of nearly every American . Researchers have linked exposure to PFAS to testicular and kidney cancers, developmental delays in children, decreased fertility, liver damage and thyroid disease. The man-made chemicals are so long-lasting that scientists haven’t been able to reliably identify how long it might take for them to break down.

PFAS-related lawsuits have already targeted manufacturers in the United States, including DuPont, its spinoff Chemours, and 3M. Last year, 3M agreed to pay at least $10 billion to water utilities across the United States that had sought compensation for cleanup costs. Thirty state attorneys general have also sued PFAS manufacturers, accusing the manufacturers of widespread contamination.

But experts say the legal battle is just beginning. Under increasing scrutiny are a wider universe of companies that use PFAS in their products. This month, plaintiffs filed a class-action lawsuit against Bic, accusing the razor company for failing to disclose that some of its razors contained PFAS.

Bic said it doesn’t comment on pending litigation, and said it had a longstanding commitment to safety.

The Biden administration has moved to regulate the chemicals, for the first time requiring municipal water systems to remove six types of PFAS . Last month, the Environmental Protection Agency also designated two of those PFAS chemicals as hazardous substances under the Superfund law, shifting responsibility for their cleanup at contaminated sites from taxpayers to polluters.

Both rules are expected to prompt a new round of litigation from water utilities, local communities and others suing for cleanup costs.

“To say that the floodgates are opening is an understatement,” said Emily M. Lamond, an attorney who focuses on environmental litigation at the law firm Cole Schotz. “Take tobacco, asbestos, MTBE, combine them, and I think we’re still going to see more PFAS-related litigation,” she said, referring to methyl tert-butyl ether, a former harmful gasoline additive that contaminated drinking water. Together, the trio led to claims totaling hundreds of billions of dollars.

PFAS were an industrial marvel when chemists at Dupont in the 1940s synthesized the material, a remarkably durable compound resistant to water, stains, heat and grease. It quickly became a mainstay in DuPont’s Teflon nonstick pans and 3M’s Scotchgard fabric protector. A powerful fire suppressant, it helped firefighters battle flames. Today, they are used for everyday items as varied as microwave popcorn bags, shampoos, raincoats and firefighting foam.

But the very qualities that have made PFAS so valuable have also prevented them from breaking down naturally in the environment. As PFAS entered the environment from factories, products and landfills, the chemicals have started to accumulate in water, air and soil.

Industry documents released through litigation show that manufacturers found adverse health effects from PFAS exposure as early as 1961 . But it wasn’t until the early 2000s that questions increasingly emerged in public about their safety. In 2005, the E.P.A. fined DuPont $10 million , at that time the largest administrative fine ever levied by the agency, for failing to disclose PFAS’s adverse effects.​​

All that has set the stage for a potential legal storm. Unlike tobacco, used by only a subset of the public, “pretty much every one of us in the United States is walking around with PFAS in our bodies,” said Erik Olson, senior strategic director for environmental health at the Natural Resources Defense Council. “And we’re being exposed without our knowledge or consent, often by industries that knew how dangerous the chemicals were, and failed to disclose that,” he said. “That’s a formula for really significant liability.”

Sandy Wynn-Stelt of Belmont, Mich., brought one early case. A year after she lost her husband to liver cancer in 2016, she discovered that the Christmas tree farm in front of her home, which had seemed such an idyllic setting, had been a dumping ground for PFAS-laden tannery waste from Wolverine World Wide, the maker of Hush Puppies shoes.

Wolverine had been among the first to license 3M’s Scotchgard for its waterproof footwear. Mrs. Wynn-Stelt got her blood tested, and found PFAS levels hundreds of times the norm. In 2020, she was diagnosed with thyroid cancer.

She sued Wolverine and 3M, and reached a settlement in 2021. Separately, nearly 2,000 local residents settled a class-action lawsuit against Wolverine. The region’s water source remains polluted with PFAS.

“Those lawyers are exactly right. This is going to be huge, now that people are starting to hold companies accountable,” Mrs. Wynn-Stelt said.

Wolverine declined to comment. 3M said it continued to “address PFAS litigation by defending itself in court or through negotiated resolutions.”

Much of the course of future litigation hinges on the evidence over PFAS’s health risks. There is broad scientific consensus that certain PFAS chemicals are harmful. “There’s a weight of evidence,” said Linda Birnbaum, a toxicologist and the former director of the National Institute of Environmental Health Sciences. “Multiple studies by different investigators, and in different populations.”

Max Swetman, another MG+M partner who presented with Mr. Gross at the February industry conference, addressed the research in his remarks to the group. “There’s a whole lot of new science being created,” he said. “It’s not the best for us.”

Still, some of the research could be vulnerable to criticism, he said. Getting the right experts to testify was crucial, he said. “Epidemiologists, if you get the right one, is always going to be your best expert in trial.”

Mr. Swetman was unavailable to comment on his remarks, according to his law firm.

One challenge facing medical research lies in the sheer number of different PFAS chemicals that have now entered the environment, each of which can have slightly different health effects, said Steph Tai, associate dean at the University of Wisconsin’s Nelson Institute for Environmental Studies and an expert in the use of science in environmental protection and litigation.

“The other thing, too, is that it takes a long time for health effects to show up,” Dr. Tai said, so the only way that scientists have been able to assess those effects is through long-term studies. Researchers must essentially look for what is referred to as “natural experiments,” according to Dr. Tai, comparing people who are naturally less exposed to PFAS with those who are more exposed. That inevitably leads to some uncertainties.

The industry has scored some major victories. Last November, the United States Court of Appeals for the Sixth Circuit tossed out a lawsuit that would have covered every Ohio citizen in a major case over exposure to PFAS, ruling that a firefighter who brought the lawsuit failed to prove that the PFAS found in his blood specifically came from the companies he sued.

3M phased out most uses of two of the most widely used PFAS chemicals, PFOS and PFOA, in the early 2000s, and DuPont in 2015 stopped using PFOA. 3M has said it will phase out the manufacturing of PFAS chemicals by the end of next year. The company will also work to discontinue their use in products, though that’s contingent on the company finding substitutes.

“As the science and technology of PFAS, societal and regulatory expectations, and our expectations of ourselves have evolved, so has how we manage PFAS,” 3M said.

DuPont referred inquiries to Chemours, the company that was spun off in 2015. Chemours declined to comment.

A long and difficult cleanup is beginning. President Biden’s 2021 infrastructure law provides $9 billion to help communities address PFAS contamination, and the E.P.A. has said $1 billion of that money would be set aside to help states with initial testing and treatment. Meantime, new kinds of PFAS are still being released into the environment. Scientists are working to learn more about them.

Hiroko Tabuchi covers the intersection of business and climate for The Times. She has been a journalist for more than 20 years in Tokyo and New York. More about Hiroko Tabuchi

The Proliferation of ‘Forever Chemicals’

Pfas, or per- and polyfluoroalkyl substances, are hazardous compounds that pose a global threat to human health..

For the first time, the U.S. government is requiring municipal water systems to detect and remove PFAS from drinking water .

A global study found harmful levels of PFAS  in water samples taken far from any obvious source of contamination.

Virtually indestructible, PFAS are used in fast-food packaging and countless household items .

PFAS lurk in much of what we eat, drink and use, but scientists are only beginning to understand how they affect our health .

Though no one can avoid forever chemicals entirely, Wirecutter offers tips on how to limit your exposure .

Scientists have spent years searching for ways to destroy forever chemicals. In 2022, a team of chemists found a cheap, effective method to break them down .